(A free translation of the original in Portuguese)

Ouro Fino Saúde Animal Participações S.A.

Quarterly Information (ITR) at June 30, 2015 and report on review of quarterly information

(A free translation of the original in Portuguese)

Report on review of quarterly information

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Ouro Fino Saúde Animal Participações S.A., included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2015, comprising the balance sheet as at that date and the statements of income, comprehensive income, changes in equity and cash flows for the quarter and six-month period then ended, and a summary of significant accounting policies and other explanatory information.

Management is responsible for the preparation of the parent company interim accounting information in accordance with the accounting standard CPC 21, Interim Financial Reporting, issued by the Brazilian Accounting Pronouncements Committee (CPC), and of the consolidated interim accounting information in accordance with CPC 21 and International Accounting Standard (IAS) 34, Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Ouro Fino Saúde Animal Participações S.A.

Conclusion on the interim information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34, applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

Other matters

Statements of value added

We have also reviewed the parent company and consolidated statements of value added for the six-month period ended June 30, 2015. These statements are the responsibility of the Company's management and are required to be presented in accordance with standards issued by the CVM applicable to the preparation of Quarterly Information (ITR) and are considered supplementary information under International Financial Reporting Standards (IFRS), which do not require the presentation of the statement of value added. These statements have been submitted to the same review procedures described above and, based on our review, nothing has come to our attention that causes us to believe that they have not been prepared, in all material respects, in a manner consistent with the parent company and consolidated interim accounting information taken as a whole.

Ribeirão Preto, August 11, 2015

PricewaterhouseCoopers
Auditores Independentes
CRC 2SP000160/O-5 "F"

Maurício Cardoso de Moraes
Contador CRC 1PR035795/O-1 "T" SP

(A free translation of the original in Portuguese)

Contents

Ouro Fino Saúde Animal Participações S.A.

Balance sheet

All amounts in thousands of reais (A free translation of the original in Portuguese)

		Parent company		Consolidated	
Assets	**Note**	**June 30, 2015**	**December 31, 2014**	**June 30, 2015**	**December 31, 2014**
Current assets					
Cash and cash equivalents	7	26	11	19,508	72,453
Trade receivables	9			175,354	178,111
Derivative financial instruments	8			2,785	10,376
Inventories	10			119,369	86,848
Taxes recoverable	11	96	96	6,107	6,905
Income tax and social contribution recoverable				1,297	2,486
Related parties	12	4,085	4,398	1,403	998
Other assets		14	12	7,278	7,439
		4,221	4,517	333,101	365,616
Non-current assets					
Long-term receivables					
Taxes recoverable	11			26,989	22,529
Deferred income tax and social contribution	13			4,878	1,920
Related parties	12	25,000	104,260		
Other assets				1,451	261
		25,000	104,260	33,318	24,710
Investments in subsidiaries	14	324,457	231,169		
Intangible assets	15			71,831	66,300
Property, plant and equipment	16			176,542	170,635
Total non-current assets		349,457	335,429	281,691	261,645
Total assets		353,678	339,946	614,792	627,261

Ouro Fino Saúde Animal Participações S.A.

Balance sheet
All amounts in thousands of reais **(continued)**

		Parent company		Consolidated	
Liabilities and equity	**Note**	**June 30, 2015**	**December 31, 2014**	**June 30, 2015**	**December 31, 2014**
Current liabilities					
Trade payables				33,918	22,390
Derivative financial instruments	8			1,307	12
Borrowings	17			64,167	103,093
Salaries and social charges		63	64	22,772	24,912
Taxes payable		19	434	4,022	5,638
Income tax and social contribution payable				3,363	763
Dividends and interest on capital	12		8,959		8,959
Related parties	12	128		284	
Commissions on sales				5,533	5,669
Other liabilities		83	420	4,841	5,468
		293	9,877	140,207	176,904
Non-current liabilities					
Derivative financial instruments	8				1,164
Borrowings	17			118,262	112,560
Provision for contingencies	18			2,827	2,664
Deferred income tax and social contribution	13				3,812
				121,089	120,200
Total liabilities		293	9,877	261,296	297,104
Equity	19				
Capital		298,889	298,889	298,889	298,889
Capital reserve		(6,392)	(6,275)	(6,392)	(6,275)
Options granted		746		746	
Revenue reserves		18,205	22,136	18,205	22,136
Carrying value adjustments		15,564	15,319	15,564	15,319
Retained earnings		26,373		26,373	
		353,385	330,069	353,385	330,069
Non-controlling interests				111	88
Total equity		353,385	330,069	353,496	330,157
Total liabilities and equity		353,678	339,946	614,792	627,261

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of income

All amounts in thousands of reais unless otherwise stated (A free translation of the original in Portuguese)

		Parent company			
	Note	**Quarter ended 6/30/2015**	**Six-month period ended 6/30/2015**	**Quarter ended 6/30/2014**	**Period from 4/10/2014 to 6/30/2014**
General and administrative expenses	22	(321)	(798)		
Equity in the earnings of subsidiaries		19,193	27,163	15,058	15,058
Other income, net	23	22	39		
Operating profit		18,894	26,404	15,058	15,058
Finance income		1	3		
Finance costs		(13)	(34)		
Finance result	24	(12)	(31)		
Profit for the period		18,882	26,373	15,058	15,058

Ouro Fino Saúde Animal Participações S.A.

Statement of income

All amounts in thousands of reais unless otherwise stated **(continued)**

		Consolidated			
	Note	**Quarter ended 6/30/2015**	**Six-month period ended 6/30/2015**	**Quarter ended 6/30/2014**	**Period from 4/10/2014 to 6/30/2014**
Revenue	21	132,696	219,740	88,208	88,208
Cost of sales	22	(59,840)	(95,556)	(38,524)	(38,524)
Gross profit		72,856	124,184	49,684	49,684
Selling expenses	22	(41,115)	(74,232)	(24,396)	(24,396)
General and administrative expenses	22	(9,424)	(18,106)	(2,574)	(2,574)
Other income (expenses), net	23	824	869	(190)	(190)
Operating profit		23,141	32,715	22,524	22,524
Finance income		722	17,042	1,633	1,633
Finance costs		(2,485)	(19,536)	(3,325)	(3,325)
Finance result	24	(1,763)	(2,494)	(1,692)	(1,692)
Profit before taxation		21,378	30,221	20,832	20,832
Income tax and social contribution	25				
Current		(9,256)	(10,604)	(3,264)	(3,264)
Deferred		6,760	6,770	(2,181)	(2,181)
Profit for the period		18,882	26,387	15,387	15,387
Attributable to:					
Owners of the parent company		18,882	26,373	15,058	15,058
Non-controlling interests			14	329	329
		18,882	26,387	15,387	15,387
Earnings per share attributable to owners of the parent company during the period (in reais)					
Basic earnings per share		0.35004	0.48891	0.30216	0.30216
Diluted earnings per share		0.34987	0.48872	0.30216	0.30216

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of comprehensive income

All amounts in thousands of reais (A free translation of the original in Portuguese)

	Parent company			
	Quarter ended 6/30/2015	**Six-month period ended 6/30/2015**	**Quarter ended 6/30/2014**	**Period from 4/10/2014 to 6/30/2014**
Profit for the period	18,882	26,373	15,058	15,058
Other components of comprehensive income				
Items that will be reclassified to profit or loss				
Payables to minority stockholders			(2,819)	(2,819)
Foreign exchange variations of the investment in the subsidiary located abroad	(194)	245	(16)	(16)
Total comprehensive income for the period	18,688	26,618	12,223	12,223

	Consolidated			
	Quarter ended 6/30/2015	**Six-month period ended 6/30/2015**	**Quarter ended 6/30/2014**	**Period from 4/10/2014 to 6/30/2014**
Profit for the period	18,882	26,387	15,387	15,387
Other components of comprehensive income				
Items that will be reclassified to profit or loss				
Payables to minority stockholders			(2,819)	(2,819)
Foreign exchange variations of the investment in the subsidiary located abroad	(201)	254	(16)	(16)
Total comprehensive income for the period	18,681	26,641	12,552	12,552
Attributable to:				
Owners of the parent company	18,688	26,618	12,223	12,223
Non-controlling interests	(7)	23	329	329
	18,681	26,641	12,552	12,552

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of changes in equity

All amounts in thousands of reais (A free translation of the original in Portuguese)

		Attributable to owners of the parent company									
					Revenue reserves						
	Note	Capital	Capital reserve	Options granted	Legal reserve	Profit retention reserve	Carrying value adjustments	Retained earnings	Total	Non-controlling interests	Total equity
Contributions by owners											
Payment of capital on April 10, 2014		1							1		1
Net assets merged	19(a)	188,626					15,208		203,834		203,834
Non-controlling interests										1,907	1,907
Total contributions by owners		188,627					15,208		203,835	1,907	205,742
Comprehensive income for the period											
Profit for the period								15,058	15,058	329	15,387
Payables to minority stockholders							(2,819)		(2,819)		(2,819)
Foreign exchange variations of the subsidiary located abroad							(16)		(16)		(16)
Total comprehensive income (loss) for the period							(2,835)	15,058	12,223	329	12,552
At June 30, 2014		188,627					12,373	15,058	216,058	2,236	218,294
At January 1, 2015		298,889	(6,275)		1,886	20,250	15,319		330,069	88	330,157
Comprehensive income for the period											
Profit for the period								26,373	26,373	14	26,387
Foreign exchange variations of the subsidiary located abroad							245		245	9	254
Total comprehensive income for the period							245	26,373	26,618	23	26,641
Contributions by owners											
Distribution of additional dividends for 2014	19(c)					(3,931)			(3,931)		(3,931)
Share options granted	19(e)			746					746		746
Borrowing costs	19(b)		(117)						(117)		(117)
Total contributions by owners			(117)	746		(3,931)			(3,302)		(3,302)
At June 30, 2015		298,889	(6,392)	746	1,886	16,319	15,564	26,373	353,385	111	353,496

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of cash flows

All amounts in thousands of reais (A free translation of the original in Portuguese)

	Note	Six-month period ended 6/30/2015 Parent company	Six-month period ended 6/30/2015 Consolidated	Period from 4/10/2014 to 6/30/2014 Parent company	Period from 4/10/2014 to 6/30/2014 Consolidated
Cash flows from operating activities					
Profit before taxation		26,373	30,221	15,058	20,832
Adjustments for:					
Reversal of impairment of trade receivables	9		(394)		(130)
Provision for inventory losses and write-offs	10		138		771
Provision for losses on advances					242
Equity in the earnings of subsidiaries	14	(27,163)		(15,058)	
Depreciation and amortization			9,342		2,828
Provision for impairment of intangible assets					766
Gains on disposal of property, plant and equipment			(127)		(312)
Interest and monetary and foreign exchange variations, net			14,000		1,498
Unrealized derivative financial instruments			(8,741)		(3)
Provision for (reversal of) contingencies	18		163		(911)
Share options granted		11	746		
Changes in working capital					
Trade receivables			2,777		(33,591)
Inventories			(32,097)		(2,832)
Taxes recoverable			(3,295)		1,621
Other assets		(55)	(1,342)		1,512
Trade payables			10,466		5,923
Taxes and charges payable		(472)	(1,176)		(3,389)
Other liabilities		(272)	(1,709)		2,183
Cash provided by (used in) operations		(1,578)	18,972		(2,992)
Interest paid			(4,294)		(1,345)
Income tax and social contribution paid			(7,050)		
Cash provided by (used in) operating activities		(1,578)	7,628		(4,337)
Cash flows from investing activities					
Advances for future capital increase		(25,000)			
Investments in intangible assets	15		(9,729)		(3,045)
Purchases of property, plant and equipment	16		(11,544)		(2,829)
Receipts of dividends and interest on capital		39,482			
Proceeds from sale of property, plant and equipment			606		708
Net cash provided by (used in) investing activities		14,482	(20,667)		(5,166)
Cash flows from financing activities					
Proceeds from borrowings			43,500		17,620
Repayment of borrowings			(86,769)		(7,311)
Borrowings received - related parties					8,600
Borrowings repaid - related parties					(13,780)
Payment of dividends and interest on capital		(12,889)	(12,889)		
Realized derivative financial instruments			16,463		
Net cash provided by (used in) financing activities		(12,889)	(39,695)		5,129
Increase (decrease) in cash and cash equivalents		15	(52,734)		(4,374)
Cash and cash equivalents at the beginning of the period		11	72,453		14,424
Exchange losses on cash and cash equivalents			(211)		(21)
Cash and cash equivalents at the end of the period	7	26	19,508		10,029

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of value added

All amounts in thousands of reais (A free translation of the original in Portuguese)

	Six-month period ended 6/30/2015		Period from 4/10/2014 to 6/30/2014	
	Parent company	Consolidated	Parent company	Consolidated
Revenues				
Gross sales and services		241,875		97,079
Other income		208		(131)
Income related to the construction of own assets		7,805		4,296
Provision for impairment of trade receivables		394		130
		250,282		101,374
Inputs acquired from third parties				
Cost of sales and services rendered		(76,778)		(30,659)
Materials, electricity, third-party services and other	(407)	(57,737)		(19,466)
Losses on assets, net		(3)		(2,113)
	(407)	(134,518)		(52,238)
Gross value added	(407)	115,764		49,136
Depreciation and amortization		(9,342)		(2,828)
Net value added generated by the entity	(407)	106,422		46,308
Value added received through transfer				
Equity in the earnings of subsidiaries	27,163		15,058	
Finance income	3	17,042		1,633
Royalties	50	50		
Other		990		214
Total value added to distribute	26,809	124,504	15,058	48,155
Distribution of value added				
Personnel				
Salaries and wages	326	45,397		13,488
Benefits	2	8,135		2,491
FGTS		3,546		991
Taxes, charges and contributions				
Federal	73	17,315		10,040
State	1	258		1,737
Municipal		183		54
Remuneration of third party capital				
Interest	34	19,764		3,269
Rentals		3,265		517
Other		254		181
Remuneration of own capital				
Profits reinvested	26,373	26,373	15,058	15,058
Non-controlling interests		14		329
Value added distributed	26,809	124,504	15,058	48,155

The accompanying notes are an integral part of this quarterly information.

1 General information

Ouro Fino Saúde Animal Participações S.A. (the "Company") is a listed corporation headquartered in Cravinhos, state of São Paulo It was established on April 10, 2014 and its objective and main activity is the investment in companies operating in the animal health industry (production and sale of veterinary drugs, vaccines and other products for production and domestic animals).

At the Extraordinary General Meeting held on June 30, 2014, the stockholders approved the merger of net assets consisting of investments, net of corresponding carrying value adjustments, of Ouro Fino Saúde Animal Ltda. (and its subsidiary Ouro Fino de México, S.A. de CV), Ouro Fino Agronegócio Ltda. and Ouro Fino Pet Ltda., in the net amount of R$ 188,626, based on an appraisal report at book value as of April 30, 2014, issued by independent appraisers on June 24, 2014.

The issue of this parent company and consolidated interim accounting information was authorized by the Company's Board of Directors on August 5, 2015.

The economic group of which the Company and its subsidiaries are part (hereinafter referred to as the "Ouro Fino Group" or the "Group") comprises the following companies:

(a) Ouro Fino Saúde Animal Participações S.A.

Ouro Fino Saúde Animal Participações S.A. is a listed corporation headquartered in Cravinhos, state of São Paulo, and registered with the São Paulo Futures, Commodities and Securities Exchange - BM&FBovespa S.A. ("BM&FBovespa") in the Novo Mercado (New Market) category. Its objective and main activity is the direct or indirect investment in the subsidiaries listed below.

On October 17, 2014, the Group completed the Public Offer of the primary and secondary distribution of its common shares. The public offering was carried out on the OTC market, as established in CVM Instruction 400. In this context, 1,923,077 common shares were issued at R$ 27.00 per share, resulting in a capital increase of R$ 51,923, which was approved by the Board of Directors at a meeting held on October 17, 2014.

Also, on November 18, 2014, the exercise of the Supplementary Stock Option took place, with the issue of 2,019,230 common shares by the Company, at R$ 27.00 per share, resulting in a capital increase of R$ 54,520, which was approved by the Board of Directors at a meeting held on November 18, 2014.

All amounts in thousands of reais unless otherwise stated

The table below shows the number of the Company's common shares held by holders of not less than 5% of common shares and by members of management:

	Common shares	%
Jardel Massari	14,834,135	27.50
Norival Bonamichi	14,834,135	27.50
General Atlantic	8,850,407	16.41
BNDESPar	6,666,788	12.36
Dolivar Coraucci Neto	801,845	1.49
Fábio Lopes Júnior	801,845	1.49
Other	7,153,152	13.26
Total	53,942,307	100.00

(b) Ouro Fino Saúde Animal Ltda.

This subsidiary, headquartered in Cravinhos, state of São Paulo, has as its objective and main activity the research, development, production and sale of veterinary drugs, vaccines and products. The sales in the domestic market are carried out through the companies mentioned in items (c) and (d) below. The sales in the foreign market are carried out directly with third parties and through the company mentioned in item (e) below. This company also provides manufacturing services to order from third parties.

On May 30, 2014, the Ministry of Agriculture, Cattle Breeding and Supply (MAPA) published Regulatory Instruction (IN) 13, effective on the same date, which resolved to "prohibit the manufacture, processing, fractionation, sale, import and use of long-acting veterinary products having macrocyclic lactones (avermectins) as their active ingredients, and that could be used in the food of any animal or insect" and suspended, as from its effectiveness, the registrations granted to finished products for veterinary use until MAPA carried out studies on the subject.

Considering that the Group had in its portfolio certain products that could be considered as subject to the provisions of this IN, on the same date management decided to record a provision for the risk of non-realization of those inventories and intangible assets, in the amounts of R$ 293 and R$ 340, respectively.

On March 27, 2015, the MAPA repealed Regulatory Instruction (IN) 13. A new IN permitting the use of these products was signed and published in the Federal Official Gazette (*Diário Oficial da União*). Therefore, the balances provided for as mentioned above were reversed on the same date.

(c) Ouro Fino Agronegócio Ltda.

This company is headquartered in Cravinhos, state of São Paulo, and has as its main activities the sale in the domestic market of veterinary drugs and products for production animals (cattle, pigs, poultry, sheep, horses and goats) acquired from the company mentioned in item (b) above.

(d) Ouro Fino Pet Ltda.

This subsidiary, headquartered in Vinhedo, state of São Paulo, has as its main activity the sale in the domestic market of veterinary drugs and products and related goods for domestic animals (cats, dogs and ornamental birds) purchased from the company mentioned in item (b) above.

(e) Ouro Fino de México, S.A. de CV

A subsidiary of Ouro Fino Saúde Animal Ltda. (96.43% equity interest), headquartered in Guadalajara, Mexico. Its main activity is the sale, exclusively in Mexico, of veterinary drugs and products purchased from its parent company.

2 Summary of significant accounting policies

The main accounting policies applied in the preparation of these parent company and consolidated interim accounting information are set out below. These policies have been consistently applied in the parent company and in its subsidiaries.

2.1 Basis of preparation

The interim accounting information was prepared in accordance with the Brazilian technical pronouncement CPC 21 - Interim Financial Reporting, and with international accounting standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and is presented in accordance with the standards issued by the Brazilian Securities Commission (CVM) applicable to the preparation of quarterly information (ITR).

The preparation of the interim accounting information requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the parent company and consolidated interim accounting information, are disclosed in Note 3.

(a) Parent company accounting information

The parent company interim accounting information was prepared in accordance with the Brazilian technical pronouncement CPC 21 - Interim Financial Reporting and with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB).

This parent company accounting information is disclosed together with the consolidated interim accounting information.

(b) Consolidated accounting information

The consolidated interim accounting information was prepared and is being presented in accordance with the Brazilian technical pronouncement CPC 21 - Interim Financial Reporting, and with the International Accounting Standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB).

The presentation of the parent company and consolidated Statement of value added is required by Brazilian corporate legislation and the accounting practices adopted in Brazil applicable to listed companies. The International Financial Reporting Standards (IFRS) do not require the presentation of this statement. Consequently, for IFRS purposes, this statement is presented as supplementary information.

(c) Changes in accounting policies and disclosures

In 2015, new standards and revisions of CPCs/IFRS became effective and were adopted by the Company and its subsidiaries, when applicable. Of these standards, the only one that is significant for the Company and its subsidiaries is the following:

Review CPC 07 - "Equity Method in Separate Financial Statements", changes the wording of CPC 35 - "Separate Financial Statements" and includes changes made by the IASB in the IAS 27 - Separate Financial Statements, and permits the adoption of the equity method of accounting for subsidiaries in separate financial statements, thus aligning the Brazilian accounting practices with international accounting standards.

Other amendments and interpretations which are effective for 2015 are not relevant for the Group.

2.2 Consolidation

The following accounting policies are applied in the preparation of the consolidated interim accounting information.

(a) Subsidiaries are all entities over which the Group has control. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

(b) Transactions, balances and unrealized gains between Group companies are eliminated. Unrealized losses are also eliminated, unless the transaction provides evidence of impairment of the asset transferred. The accounting policies of subsidiaries are changed, where necessary, to ensure consistency with the policies adopted by the Group.

2.3 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The Group's chief operating and strategic decision-maker, who is responsible for allocating resources and assessing the performance of the operating segments, is the Board of Directors.

2.4 Foreign currency translation

(a) Functional and presentation currency

Items included in the interim accounting information of each of the Group companies are measured using the currency of the primary economic environment in which the entities operate (the "functional currency"), which is substantially the Brazilian real, except as mentioned in item (c) below. Therefore, the parent company and consolidated interim accounting information is presented in this currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation, when items are measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of income as "Finance income or costs".

(c) Group companies with a functional currency different from the Brazilian real

The results of operations and the financial position of Ouro Fino de México, S.A. de CV (subsidiary of Ouro Fino Saúde Animal Ltda.), whose functional currency is different from the presentation currency, are translated into the presentation currency as follows:

(i) Assets and liabilities for each balance sheet presented are translated at the closing rate of the balance sheet date.

(ii) Income and expenses for each statement of income are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions).

(iii) All resulting exchange differences are recognized as a separate component of equity in "Carrying value adjustments".

2.5 Cash and cash equivalents

Cash and cash equivalents includes cash on hand, bank deposits and other short-term highly liquid investments with original maturities of three months or less and with immaterial risk of change in value.

2.6 Financial assets

2.6.1 Classification

The Group classifies its financial assets, at initial recognition, in the following categories: loans and receivables and measured at fair value through profit or loss. The classification depends on the purpose for which the financial assets were acquired.

(a) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, and which are not classified in the "at fair value through profit or loss" category. They are included in current assets, except for maturities greater than 12 months after the end of the reporting period, which are classified as non-current assets. Loans and receivables comprise trade and other receivables and cash and cash equivalents in the balance sheet.

(b) Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are financial assets held for trading. A financial asset is classified in this category if acquired principally for the purpose of selling in the short-term. All financial assets in this category are classified as current assets. Derivatives are also classified as "held for trading".

2.6.2 Recognition and measurement

Normal purchases and sales of financial assets are recognized on the trade date. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the statement of income. Financial assets are derecognized when the rights to receive cash flows have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. Financial assets at fair value through profit or loss are subsequently carried at fair value.

Loans and receivables are carried at amortized cost using the effective interest rate method.

2.6.3 Offsetting of financial instruments

Financial assets and liabilities are offset and the net amount presented in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. The legal right should not be contingent on the occurrence of future events and should be applicable in the ordinary course of business, and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

2.6.4 Impairment of financial assets

Assets carried at amortized cost

Management assesses at the balance sheet date whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

2.7 Derivative financial instruments

Derivative financial instruments are contracted with the purpose of hedging transactions against the risks of fluctuations in foreign exchange and interest rates, and are not used for speculative purposes. The Group mainly operates with exchange rate and interest rate swap contracts. Derivatives are recognized at fair value on the date a derivative contract is entered into and are subsequently remeasured at their fair value. Since the Group does not adopt hedge accounting, the changes in the fair value of derivative instruments are recognized immediately in the statement of income within "Finance result".

2.8 Trade receivables

Trade receivables are stated at the original sales amount, plus, when applicable, monetary and foreign exchange variations, and less the provision for impairment of trade receivables. If collection is expected in one year or less, the receivables are classified as current assets. If not, they are presented as non-current assets.

Impairment is established when there is objective evidence that the companies will not be able to recover all the amounts due. The calculation of the provision is based on a reasonable estimate to cover probable losses on the realization of receivables, taking into consideration the situation of each customer and respective guarantees.

2.9 Inventories

Inventories are stated at the lower of average cost of purchase or production and net realizable value. Cost is determined using the weighted average fixed method. The cost of finished products and work in process comprises raw materials, direct labor, other direct costs and related general production expenses (based on the normal operational capacity). Net realizable value is the estimated selling price in the ordinary course of business, less estimated completion costs and estimated selling expenses. Imports in transit are stated at the accumulated cost of each transaction.

2.10 Current and deferred income tax and social contribution

The income tax and social contribution expenses for the period comprise current and deferred taxes. Income taxes are recognized in the statement of income, except to the extent that they relate to items recognized directly in equity. In this case, the taxes are also recognized directly in equity.

The current and deferred income tax and social contribution are calculated on the basis of the tax laws enacted at the balance sheet date in the countries where the Group entities operate and generate taxable income. The currently defined tax rates in Brazil of 25% for income tax and 9% for social contribution are utilized to calculate deferred taxes.

The current and deferred income tax and social contribution are presented net, separated by taxpaying entity, in liabilities when there are amounts payable, or in assets when the amounts prepaid exceed the total amount due on the reporting date.

Deferred income tax and social contribution are recognized on accumulated tax losses and temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements. They are determined based on tax rates in effect on the balance sheet date and which are expected to apply when the related deferred tax asset is realized or the deferred tax liability is settled.

Deferred tax assets are recognized only to the extent it is probable that future taxable profit will be available against which the temporary differences and/or tax losses can be utilized.

Ouro Fino Pet Ltda. calculates income tax and social contribution under the deemed profit method. The deemed profit system is a simplified taxation method to determine the calculation basis of corporate entities that are not obliged, in the calendar year, to use the taxable profit method, or whose total gross revenue is equal to or lower than R$ 78,000.

2.11 Intangible assets

(a) Research and development of products

Research expenditures are recognized as expenses when incurred. Expenditures incurred in the development of products are recognized as intangible assets only if the cost can be reliably measured and when it is probable that they will bring future economic benefits.

The Group evaluates projects based on its own methodology, which considers various analysis structures, and that the projects will be successful from the development of "pilots" of the products made according to the requirements of regulatory bodies, accompanied by analyses of financial feasibility.

Capitalized development expenditures are amortized as from the beginning of the sale of the product, using the straight-line method over the use of the expected benefit, which is, on average, 10 years.

The finance charges on borrowings to finance a project are capitalized during the period required to develop the products.

(b) Trademarks and licenses purchased

Separately purchased trademarks and licenses are initially stated at historical cost. Since trademarks and licenses have a defined useful life, they are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives of approximately 10 years.

(c) Computer software

Computer software licenses acquired are capitalized on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortized over their estimated useful lives of five years on the straight line method.

Costs associated with maintaining computer software are recognized as an expense, as incurred.

2.12 Property, plant and equipment

Property, plant and equipment are stated at historical cost, less accumulated depreciation. This cost was adjusted in subsidiaries to reflect the deemed cost of land on the date of transition to IFRS/CPCs, and is calculated on the straight-line method, considering the estimated useful lives of the respective assets. The annual depreciation rates are disclosed in Note 16. Subsequent costs are included in an asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part or item is derecognized. All other repairs and maintenance are charged to the statement of income when incurred.

If the carrying amount of an asset is higher than its recoverable value, the Group records a provision for impairment to adjust the carrying amount to the estimated recoverable value.

The costs of borrowings used to finance the construction of property, plant and equipment are capitalized during the period necessary to construct and prepare the asset for its intended use. Gains and losses on disposal are determined by comparing the proceeds with the carrying amount and are recognized within "Other income (expenses), net" in the statement of income.

2.13 Impairment of non-financial assets

Assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized when the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.

2.14 Trade payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business and are classified as current liabilities if payment is due in one year or less. If not, they are presented as non-current liabilities. Accounts payable are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method. In practice, they are usually recorded at the amount of the related invoice.

2.15 Borrowings

Borrowings are initially recognized on the receipt of funds, net of transaction costs, and are subsequently presented at cost plus charges and interest in proportion to the time elapsed, using the effective interest rate method.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

2.16 Provisions

Provisions are recognized when there is a present or constructive obligation as a result of past events, it is probable that assets will be surrendered to settle the obligation, and a reliable estimate of the amount can be made.

2.17 Other assets and liabilities

An asset is recognized in the balance sheet when it is probable that its future economic benefits will flow to the Company and its cost or value can be reliably measured. A liability is recognized in the balance sheet when the Company has a legal or constructive obligation resulting from a past event and it is probable that economic resources will be required to settle the liability. The assets and liabilities are recorded including accrued income or incurred charges and exchange and monetary variations.

Assets and liabilities are classified as current when the realization or settlement is probable within the next 12 months. Otherwise, they are presented as non-current.

2.18 Employee benefits

(a) Private pension plan

The Group companies sponsor a defined contribution pension plan for their employees. In the defined contribution plan, the companies pay contributions to a private pension plan on contractual bases. After the contributions have been made, the companies have no further obligations for additional payments. The regular contributions comprise the net periodic costs for the period in which they are due and are included in personnel expenses.

(b) Profit sharing

The Group recognizes a liability and an expense for profit-sharing in the statement of income. These provisions are calculated based on quantitative and qualitative targets established by management and are recorded as personnel expenses in the statement of income.

(c) Share-based payments

The Company has a share-based compensation plan (stock option plan), duly approved by the Board of Directors, under which it receives services from its executives and third parties as consideration for the share options granted. The premium of these options, calculated on the grant date, is recognized as an expense against equity during the grace period.

2.19 Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of products and services in the ordinary course of the activities. Revenue is shown net of value-added tax, returns, rebates and discounts, and after eliminating sales within the Group. Revenue is recognized when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and when specific criteria have been met for each of its activities, as described below. The Group bases its estimates on historical results, taking into consideration the type of customer, the type of transaction and the specifics of each arrangement.

(a) Sales of products

The Group produces and sells a range of veterinary drugs and products for production and domestic animals.

Sales are recognized when a Group entity has delivered products to the customer and the customer has full discretion over the channel and price to resell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products.

(b) Interest income

Interest income is recognized on the accrual basis of accounting, using the effective interest method.

2.20 Other income and expenses

Other income and expenses are recognized in the statement of income on the accrual basis of accounting.

2.21 Leases

Leases of property, plant and equipment where the Group has substantially all the risks and rewards of ownership are classified as finance leases. Finance leases are capitalized at the inception of the lease at the lower of the fair value of the leased item and the present value of the minimum lease payments.

Lease obligations are included in borrowings.

2.22 Distribution of dividends and interest on capital

The distribution of dividends and interest on capital to stockholders is recognized as a liability in the interim accounting information based on the Company's bylaws. Any amount that exceeds the minimum required is only provisioned on the date it is approved by the stockholders at the Ordinary General Meeting.

The tax benefit of interest on capital is recognized in the statement of income, because in substance it represents a decrease in the effective rate of income tax and social contribution.

2.23 New standards, amendments and interpretations to existing standards that are not yet effective

The following new standards and interpretations to existing standards were issued by the IASB but are not effective for June 30, 2015. The early adoption of standards, even though encouraged by the IASB, has not been implemented in Brazil by the Brazilian Accounting Pronouncements Committee (CPC).

- IFRS 9, "Financial instruments" addresses the classification, measurement and recognition of financial assets and financial liabilities. The full version of IFRS 9 was published in July 2014, effective on January 1, 2018. It replaces the parts of IAS 39 that relate to the classification and measurement of financial instruments. IFRS 9 maintains, but simplifies, the combined measurement model, and establishes three main categories of measurement of financial assets: amortized cost, fair value through other comprehensive income and fair value through profit or loss. It also includes a new model of expected credit losses, which replaces the existing incurred losses model. IFRS 9 mitigates the requirements of hedge effectiveness and requires an economic relationship between the hedged item and the hedging instrument, and that the hedge ratio be the same as that which management effectively uses for risk management purposes. Management is assessing the full impact of the adoption of IFRS 9.

- IFRS 15 - "Revenue from Contracts with Clients", specifies how and when revenue must be recognized, as well as defines rules for disclosure of relevant information. IFRS 15 was issued in May 2014 and replaces IAS 18 - "Revenue", IAS 11 - "Construction Contracts" and several interpretations related to revenue. The application of this standard is mandatory for all the companies that issue financial statements for IFRS purposes and it applies to almost all contracts with clients, the main exceptions being leases, financial instruments and insurance contracts. The Group is yet to assess the full impact of IFRS 15. The standard is applicable as from January 1, 2017.

There are no other IFRS or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Group.

3 Critical accounting estimates and judgments

Accounting estimates and assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

3.1 Critical accounting estimates and assumptions

Based on assumptions, the Group makes estimates concerning the future. The resulting accounting estimates will seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next year are addressed below:

(a) Impairment of intangible assets

The Group annually tests product development balances in intangible assets for impairment, whenever possible through the discounted cash flow method, considering, among other aspects:

(i) assumptions of future revenue generation, based on market dimensions (current and expected) and on the Group's planned market share;

(ii) estimates of direct and indirect manufacturing costs; and

(iii) trading expenditures, such as marketing, commissions, freight and storage expenses.

The projection period covers five or more years as from the estimated launching date, depending on the estimates of the product's life cycle, market development and level of associated technological innovation. Provisions are recorded when the recoverable amount (net present value of cash flow) is below the amount of the recorded asset, pursuant to the Company's accounting policy presented in Note 2.13.

(b) Deferred income tax and social contribution

The deferred income tax and social contribution assets, arising from income tax and social contribution losses, were recognized based on the expectation of future realization, supported by projections of profitability made by management, which consider the typical development of business and markets, according to the currently known scenarios.

(c) Provision for contingencies

The Group is a party to labor, civil and tax lawsuits at various court levels. The provisions for contingencies to cover expected losses on litigation in process are established and updated based on management's assessment, according to the opinion of its legal counsel, and require a high level of judgment on the matters involved.

(d) Review of the useful lives of property, plant and equipment

The recovery capacity of the assets that are used in the Group's activities is evaluated whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be recoverable based on future cash flows. If the carrying amount of these assets is higher than their recoverable value, the carrying amount is adjusted and the useful lives revised to the new levels.

4 Financial risk management

4.1 Financial risk factors

The activities of the Group companies expose them to financial risks mainly related to foreign exchange variations, fluctuation in interest rates, credit and liquidity. The objective of risk management is to reduce potential unexpected variations in the results arising from these risks. The Group manages financial risks as the basis for its growth strategy and satisfactory cash flows. The Group has a Finance Committee that establishes management strategies regarding such exposures, which can include the utilization of derivative or non-derivative financial instruments for hedging potential risks.

The Group monitors the levels of exposure to each market risk (foreign exchange variation and interest rate) through an analysis based on accounting exposure and future cash flow projections.

(a) Market risk

(i) Foreign exchange risk

This risk arises from the possibility of the Group incurring unexpected losses due to fluctuations in foreign exchange rates which reduce the amount of assets and increase liabilities. The Group is mainly exposed to the fluctuation in the US dollar exchange rate.

In order to protect from foreign exchange risks, when necessary, the Group utilizes derivative transactions, mainly exchange rate swaps.

Swaps, classified as derivatives at fair value through profit or loss, were contracted to exchange the charges on borrowings initially obtained in foreign currency for charges based on the Interbank Deposit Certificate (CDI) interest rate variation, as well as to exchange interest rates initially contracted as fixed for variable rates. Gains and losses are recognized in "Finance result" in the statement of income, because hedge accounting is not currently adopted.

All amounts in thousands of reais unless otherwise stated

The following table presents the consolidated carrying amount of the assets and liabilities denominated in US dollars:

	June 30, 2015	December 31, 2014
Assets in foreign currency		
Cash and cash equivalents	1,546	2,266
Trade receivables	9,983	13,965
Advances to suppliers	10,420	10,820
	21,949	27,051
Liabilities in foreign currency		
Borrowings (*)	568	817
Trade payables	19,863	11,330
Advances from customers	118	1
	20,549	12,148
Net exposure - assets	1,400	14,903

(*) The balance of borrowings in foreign currency does not consider working capital amounting to R$ 5,905 (December 31, 2014 - R$ 63,648), because an exchange rate swap has been contracted.

The assets and liabilities denominated in foreign currency are regularly monitored through the estimated cash flows of incoming and outgoing foreign exchange assets and liabilities. The amount of assets and liabilities in foreign currency fluctuates during a year, which may or may not cause a mismatch. Consequently, in order to mitigate risks arising from foreign exchange variations, whenever required, derivative transactions may be contracted.

In the table below five scenarios are presented, considering the changes in the quotation of the Brazilian real against the US dollar.

		Impact of the appreciation/depreciation of the U.S. dollar on the portfolio balance					
		3.10	3.24	2.43	1.62	4.05	4.86
Assets/liabilities	**Risk**	**June 30, 2015**	**Scenario 1**	**Scenario 2**	**Scenario 3**	**Scenario 4**	**Scenario 5**
			(probable)	(US$ depreciation - 25%)	(US$ depreciation - 50%)	(US$ appreciation - 25%)	(US$ appreciation - 50%)
Cash and cash equivalents	US$ depreciation	1,546	68	(335)	(739)	472	876
Trade receivables	US$ depreciation	9,983	442	(2,164)	(4,770)	3,048	5,655
Advances to suppliers	US$ depreciation	10,420	461	(2,259)	(4,979)	3,182	5,902
Borrowings	US$ appreciation	568	(25)	123	271	(173)	(322)
Trade payables	US$ appreciation	19,863	(880)	4,306	9,492	(6,065)	(11,251)
Advances from customers	US$ appreciation	118	(5)	26	56	(36)	(67)
Net effect		1,400	61	(303)	(669)	428	793

(ii) Interest rate risk

This risk arises from the possibility that the Group may incur losses due to adverse fluctuations in interest rates. The Group's interest rate risk primarily arises from borrowings. The indebtedness is mainly subject to the fixed interest rates and the Interbank Deposit Certificate (CDI) rate. The Group seeks to maintain a stable relation between its long and short-term indebtedness, maintaining a higher proportion in the long-term. As regards financial investments, the index is the CDI rate.

The Group continuously monitors market interest rates in order to assess the need to contract new derivatives to hedge against the volatility risk of these rates.

The Group believes that at present the fluctuations in interest rates do not significantly affect its finance result since, at June 30, 2015, 74% (December 31, 2014 - 49.3%) of its borrowings are subject to fixed interest rates.

(b) Credit risk

The Group is potentially subject to credit risk related to trade receivables, financial investments and derivatives. To limit the risk associated with financial assets, especially financial investments, the Group carries out transactions only with leading financial institutions.

The credit risk is mitigated through the broad customer base and careful selection of customers by business segment (cattle, horses, pigs, poultry and domestic animals), in addition to the utilization of guarantees, establishment of individual exposure limits and a well-defined credit policy that utilizes credit risk modeling, through which a rating and credit risk level is attributed to each customer, based on the Group's 28 years of experience in the market.

The Group has a Credit Committee that establishes guidelines and assesses and monitors the levels of credit risk that the Group is willing to accept in the course of its business.

In addition to the risk mitigations established in its credit policies, the Group has credit insurance contracted for a portion of its sales.

The Group classifies its customer portfolio through risk evaluation methodologies developed to express the real risk of its customers. Weighting are attributed to each indicator and a rating is defined based on their combination. The Group's synthetic credit risk rating for its customers is defined according to ratings ranging from "AA" (the lowest risk) to "E" (the highest risk) (Note 6).

(c) Liquidity risk

This is the risk of the Group not having sufficient liquid funds to meet its financial commitments, due to the mismatch of terms or volume in expected receipts and payments.

The Group adopts a responsible policy for managing its financial assets and liabilities, which is monitored by the Chief Financial Officer through operating strategies to ensure liquidity, profitability and security.

All amounts in thousands of reais unless otherwise stated

Cash flow forecasting is based on the approved budget and subsequent adjustments, which takes into consideration, besides all the operating plans, the plan for raising funds to support planned investments and the maturity schedule of the debts. The Treasury area monitors daily the forecasts included in the cash flow projections to ensure the Group has sufficient cash to meet operational needs. Additionally, the Group has pre-approved credit facilities available to increase and strengthen its liquidity position.

Cash and cash equivalents are primarily invested in Bank Deposit Certificates (CDBs) and Repurchase Agreements, corresponding to highly liquid instruments.

The Group maintains its gearing ratio in a manner that does not jeopardize its payment capacity and investments. As a guideline, the highest percentage of indebtedness should be allocated to the long-term.

The table below analyzes the financial liabilities into relevant maturity groupings, based on the remaining period at the balance sheet date to the contractual maturity date.

The amounts disclosed in the table are the contractual undiscounted cash flows.

				Consolidado
	Menos de 1 ano	**Entre 1 e 2 anos**	**Entre 2 e 5 anos**	**Acima de 5 anos**
Em 30 de junho de 2015				
Fornecedores	33,918			
Empréstimos e financiamentos (*)	68,054	60,002	51,571	24,089
Instrumentos financeiros derivativos, líquidos	(1,478)			
Demais passivos	40,815	2,827		
	141,309	62,829	51,571	24,089
Em 31 de dezembro de 2014				
Fornecedores	22,390			
Empréstimos e financiamentos (*)	113,048	60,987	59,139	339
Instrumentos financeiros derivativos, líquidos	(10,364)	1,164		
Dividendos e juros sobre o capital próprio	8,959			
Demais passivos	39,248	799	1,001	7,878
	173,281	62,950	60,140	8,217

(*) As the amounts included in the table are the contractual undiscounted cash flows, and therefore include future financial charges, these amounts do not agree with the amounts disclosed on the balance sheet for borrowings.

4.2 Capital management

The Group's objectives when managing capital are to safeguard its ability to continue as a going concern in order to provide returns for stockholders, maintaining a strong credit classification in order to support business and maximize value for the stockholders.

All amounts in thousands of reais unless otherwise stated

The Group manages the capital structure and adjusts it considering changes in the economic situation. The capital structure arises from the selection between own capital (capital contributions and profit retention) and third-party capital to finance the Group's operations. The Group monitors capital on the basis of the gearing ratio, which can be measured using several indexes.

The gearing ratios at June 30, 2015 and December 31, 2014 are as follows:

		Consolidated	
	Note	June 30, 2015	December 31, 2014
Borrowings	17	182,429	215,653
Derivative financial instruments, net	8	(1,478)	(9,200)
Cash and cash equivalents	7	(19,508)	(72,453)
Net debt		161,443	134,000
Equity	19	353,496	330,157
Total capital		514,939	464,157
Gearing ratio (%)		31.35	28.87

4.3 Fair value estimation

The fair value of the financial instruments contracted by the Group is measured based on information obtained from the financial institutions and prices quoted in an active market, based on standard market pricing methodology, which comprises measuring their nominal value up to the due date and discounting this to present value at futures market rates.

The Group evaluates, at the reporting date, if there is objective evidence that a financial asset or a group of financial assets is impaired in relation to its recoverable value.

The carrying amounts of trade receivables, less provision for impairment, and payables are assumed to approximate their fair values, especially considering term and nature. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.

Financial instruments are measured in the balance sheet at fair value; this requires disclosure of fair value measurements by level of hierarchy.

All amounts in thousands of reais unless otherwise stated

All the Group's financial instruments have been classified as Level 2 "Other observable significant data", as shown below.

		Consolidated	
As per balance sheet	**Classification**	**June 30, 2015**	**December 31, 2014**
Assets - Derivative financial instruments			
Exchange rate swap	Level 2	2,785	10,376
Liabilities - Derivative financial instruments			
Interest rate swap	Level 2	(1,307)	(1,176)
		1,478	9,200

5 Financial instruments by category

	June 30, 2015			December 31, 2014		
	Parent company	Consolidated		Parent company	Consolidated	
	Loans and receivables	**Assets at fair value through profit or loss**	**Loans and receivables**	**Loans and receivables**	**Assets at fair value through profit or loss**	**Loans and receivables**
Assets as per balance sheet						
Cash and cash equivalents	26		19,508	11		72,453
Derivative financial instruments		2,785			10,376	
Accounts receivable			175,354			178,111
Related parties	29,085		1,403	108,658		998
Other assets, except prepaid expenses			5,836	12		5,458
	29,111	2,785	202,101	108,681	10,376	257,020
	Other financial liabilities	**Liabilities at fair value through profit or loss**	**Other financial liabilities**	**Other financial liabilities**	**Liabilities at fair value through profit or loss**	**Other financial liabilities**
Liabilities as per balance sheet						
Trade payables			33,918			22,390
Derivative financial instruments		1,307			1,176	
Borrowings			182,429			215,653
Dividends and interest on capital				8,959		8,959
Related parties	128		284			
Commissions on sales			5,533			5,669
Other liabilities	83		4,841	420		5,468
	211	1,307	227,005	9,379	1,176	258,139

All amounts in thousands of reais unless otherwise stated

6 Credit quality of financial assets

The credit quality of financial assets that are neither past due nor impaired is assessed by reference to external credit ratings (if available) or to historical information about counterparty default rates:

The balances of bank current accounts, repurchase agreements and bank deposits (CDBs) amounting to R$ 19,483 (December 31, 2014 - R$ 72,400) were held in leading financial institutions rated as A-2 by Standard & Poor's.

The balances of trade receivables are evaluated as described in Note 4.1 (b), as follows:

	June 30, 2015	December 31, 2014
AA	53,437	57,652
A	66,273	55,468
B	23,925	31,631
C	19,527	22,987
D	10,901	11,275
E	4,307	2,508
	178,370	181,521

7 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and at banks, as well as investments in Bank Deposit Certificates (CDBs) earning up to 101.0% of the Interbank Deposit Certificate (CDI) interest rate.

	Parent company		Consolidated	
	June 30, 2015	December 31, 2014	June 30, 2015	December 31, 2014
Cash				
In local currency			6	6
In foreign currency			19	47
			25	53
Banks				
In local currency	26	11	619	2,232
In foreign currency			1,527	2,219
	26	11	2,146	4,451
Bank Deposit Certificates (CDBs)			17,337	67,949
	26	11	19,508	72,453

All amounts in thousands of reais unless otherwise stated

8 Derivative financial instruments (consolidated)

	June 30, 2015		December 31, 2014	
	Assets	**Liabilities**	**Assets**	**Liabilities**
Foreign exchange and interest rate swaps	2,785	1,307	10,376	1,176
Non-current				(1,164)
Current	2,785	1,307	10,376	12

The fair value of the derivatives is classified as a non-current asset or liability if the remaining maturity of the item protected by the swap is more than 12 months and, as a current asset or liability, if the remaining period until maturity of the item is less than 12 months.

The notional principal amounts of the outstanding foreign exchange rate swap contracts at June 30, 2015 amount to US$ 1,875 thousand (December 31, 2014 - US$ 23,750 thousand) and of the interest rate swap contracts to R$ 20,400 thousand (December 31, 2014 - R$ 20,400 thousand).

9 Trade receivables (consolidated)

	June 30, 2015	December 31, 2014
Domestic customers	168,387	167,556
Foreign customers	9,983	13,965
Provision for impairment of trade receivables	(3,016)	(3,410)
Current	175,354	178,111

The foreign trade receivables at June 30, 2015 amounted to US$ 3,218 thousand (December 31, 2014 - US$ 5.258).

All amounts in thousands of reais unless otherwise stated

The analysis of the maturity of trade receivables is as follows:

	June 30, 2015	December 31, 2014
Falling due		
Up to 3 months	114,571	107,816
From 3 to 6 months	40,544	46,199
Over 6 months	7,095	10,760
	162,210	164,775
Past due		
Up to 3 months	7,941	10,126
From 3 to 6 months	3,263	341
Over 6 months	4,956	6,279
	16,160	16,746
	178,370	181,521

The provision for impairment of trade receivables was recorded for receivables overdue for more than 180 days and without guarantees. Management has appropriate collection procedures in relation to the other overdue receivables and believes that the Group will not incur losses.

Changes in the provision were as follows:

Merged balance	3,220
Additions	190
At December 31, 2014	3,410
Additions	329
Final write-off	(723)
At June 30, 2015	3,016

All amounts in thousands of reais unless otherwise stated

10 Inventories (consolidated)

	June 30, 2015	December 31, 2014
Finished products	48,563	33,254
Raw materials	35,774	24,347
Packaging materials	10,556	10,431
Semi-finished goods	9,180	6,568
Imports in transit	6,960	6,021
Advances to suppliers	4,568	3,672
Other	6,085	5,137
Provision for inventory losses	(2,317)	(2,582)
	119,369	86,848

The changes in the provision for inventory losses differ from the cash flow because it does not take into consideration reductions resulting from inventory adjustments amounting to R$ 403.

11 Taxes recoverable

	Parent company		Consolidated	
	June 30, 2015	December 31, 2014	June 30, 2015	December 31, 2014
ICMS			27,064	26,161
ICMS, PIS and COFINS on purchases of property, plant and equipment			724	743
IRRF	96	96	3,591	521
IPI			547	510
PIS and COFINS			190	1,402
REINTEGRA			874	
Other			106	97
	96	96	33,096	29,434
Non-current			(26,989)	(22,529)
Current	96	96	6,107	6,905

ICMS – State Value-Added Tax
PIS – Social Integration Program
COFINS - Social Contribution on Revenues
IRRF - Income Tax Withheld at Source
REINTEGRA - Special System for Refund of Tax Amounts to Exporting Companies

ICMS credits, which amounted to R$ 26,545 at June 30, 2015 (December 31, 2014 - R$ 22,058), were mainly generated by Ouro Fino Saúde Animal Ltda. These credits are generated by exempt sales in domestic transactions and sales with a 60% reduction in the calculation basis in interstate transactions, with the full/partial maintenance of credits on inputs, pursuant to ICMS Agreement 100/97.

All amounts in thousands of reais unless otherwise stated

Once the credit balances have been approved, they are considered to be appropriate according to the applicable legislation and can be utilized in the purchases of inputs and of machinery and equipment, and/or transferred to other Group companies with an interdependence relationship and which regularly calculate ICMS payable. Currently, most of these credits are under regular approval process.

All ICMS credits related to 2010, 2011 and 2012, amounting to R$ 18,846, were approved by the tax authorities, and R$ 11,048 were released for immediate use. The residual balance of R$ 7,798 has been temporarily withheld in connection with tax assessments which are being discussed at an administrative level and obligations related to the submission of electronic files under the terms of the Coordinating Committee of Tax Administration Board (CAT) Ordinance 83/2009. Up to June 30, 2015, all credits released had already been used.

REINTEGRA credits relate to the Special Tax Refund Regime for Exporters.

12 Related parties

(a) Main balances and transactions

								Parent company
								June 30, 2015
	Ouro Fino Participações e Empr. S.A.	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino Química Ltda.	Stock-holders	Other	Total
Main balances								
Current assets								
Other assets (i)			5		100	448	499	1,052
Interest on capital			3,033					3,033
Non-current assets								
Advances for future capital increase		25,000						25,000
Current liabilities								
Other liabilities (i)	28	12			10	78		128

								Six-month period ended 6/30/2015
	Ouro Fino Participações e Empr. S.A.	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino Química Ltda.	Stock-holders	Other	Total
Main transactions								
Reimbursement of Shared Services Center		(61)	5	6				(50)
Royalty income					50			50
Other expenses, net		(2)						(2)

						December 31, 2014
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Química Ltda.	Stock-holders	Other	Total
Main balances						
Current assets						
Other assets (i)			44	448	506	998
Interest on capital		3,400				3,400
Non-current assets						
Advances for future capital increase	103,410	850				104,260
Current liabilities						
Other liabilities (i)	41	151	3	78		273
Dividends and interest on capital				8,959		8,959

All amounts in thousands of reais unless otherwise stated

							Consolidated
							June 30, 2015
	Ouro Fino Participações e Empr. S.A.	Ouro Fino Química Ltda.	Condomínio Rural Ouro Fino	BNDES	Stock-holders	Other	Total
Main balances							
Current assets							
Other assets (i)	23	383	50		448	499	1,403
Current liabilities							
Other liabilities (i)	28	158	20		78		284
Borrowings				5,434			5,434

					Six-month period ended 6/30/2015
	Ouro Fino Participações e Empr. S.A.	Ouro Fino Química Ltda.	Condomínio Rural Ouro Fino	BNDES	Total
Main transactions					
Gross profit from sales of goods			27		27
Reimbursement of Shared Services Center	55	1,592			1,647
Royalty income		50			50
Other income (expenses), net	67	(17)	(350)		(300)
Finance income	46				46
Interest on borrowings				(377)	(377)

							December 31, 2014
	Ouro Fino Participações e Empr. S.A.	Ouro Fino Química Ltda.	Condomínio Rural Ouro Fino	BNDES	Stock-holders	Other	Total
Main balances							
Current assets							
Other assets (i)	28	880	78		448	506	1,940
Current liabilities							
Other liabilities (i)		222			78		300
Dividends and interest on capital					8,959		8,959
Borrowings				8,361			8,361

					Period from 4/10/2014 to 6/30/2014
	Ouro Fino Participações e Empr. S.A.	Ouro Fino Química Ltda.	Condomínio Rural Ouro Fino	BNDES	Total
Main transactions					
Reimbursement of Shared Services Center	116	3,871			3,987
Other income (expenses), net		280	(195)		85
Finance costs		(166)			(166)
Interest on borrowings				(163)	(163)

(i) Other assets and liabilities

Other assets and liabilities are represented by the reimbursement of expenses, especially expenditures with the Shared Services Center ("CSC"), according to the expense sharing agreement entered into on June 30, 2014.

All amounts in thousands of reais unless otherwise stated

(b) Key management remuneration

Key management personnel include members of the Board of Directors and the Executive Board, whose remuneration is approved by the Annual General Meeting of stockholders. The remuneration paid or payable to key management for their services is shown below:

	June 30, 2015	June 30, 2014
Salaries	1,137	252
Labor charges	72	50
Direct and indirect benefits	67	40
Variable remuneration	308	
Share-based payments (i)	257	
	1,841	342

(i) Despite the fact that management does not consider share-based payments as remuneration, the amounts under this heading are recorded in this Note, as required by Technical Pronouncement CPC 05 - Related-party Disclosures.

13 Current and deferred income tax and social contribution (consolidated)

The Company and its subsidiaries Ouro Fino Saúde Animal Ltda. and Ouro Fino Agronegócio Ltda. determine income tax and social contribution on the taxable profit method, calculated at the rates of 25% for income tax and 9% for social contribution, whereas Ouro Fino Pet Ltda. adopts the deemed profit method. The Group also has a company located in Mexico that calculates its taxes based on the regulations of that country. Therefore, there is no correlation between the amounts presented in the consolidated statement of income and the results that would have been obtained by applying the standard rates mentioned above.

The deferred tax credits arise from accumulated income tax and social contribution losses, as well as from temporary differences. Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available to offset temporary differences and/or income tax and social contribution losses, considering projections of future profitability based on internal assumptions and future economic scenarios, which are, therefore, subject to changes.

All amounts in thousands of reais unless otherwise stated

(a) Composition, nature and realization of taxes

(i) Deferred income tax and social contribution assets, net

	June 30, 2015	December 31, 2014
Tax credits on:		
Accumulated income tax and social contribution losses	2,459	
Temporary differences		
Unrealized profit in inventories	2,198	
Foreign exchange variations - on a cash basis	98	
Pre-operating expenses written-off	1,056	
Provisions	7,448	2,841
	13,259	2,841
Tax liabilities on:		
Temporary differences		
Deemed cost of land	(7,878)	
Derivative financial instruments	(503)	(921)
	(8,381)	(921)
Total assets, net	4,878	1,920

(ii) Deferred income tax and social contribution liabilities, net

	June 30, 2015	December 31, 2014
Tax credits on:		
Temporary differences		
Provisions		(4,311)
Unrealized profit in inventories		(1,460)
Pre-operating expenses written-off		(1,152)
		(6,923)
Tax liabilities on:		
Deemed cost of land		7,878
Foreign exchange variations - on a cash basis		430
Derivative financial instruments		2,208
Accelerated depreciation		219
		10,735
Total liabilities, net		3,812
Total deferred tax credits	13,259	9,764
Total deferred tax liabilities	8,381	11,656

All amounts in thousands of reais unless otherwise stated

The deferred income tax and social contribution are presented net, by entity, in the balance sheet.

The net changes in the deferred tax account were as follows:

	June 30, 2015	**December 31, 2014**
Opening balance	(1,892)	3,495
Pre-operating expenses written-off	(96)	(128)
Accumulated income tax and social contribution losses	2,459	(5,650)
Derivative financial instruments	2,626	(3,605)
Provisions	296	2,274
Unrealized profit in inventories	738	1,460
Exchange rate variations - taxation on a cash basis	528	239
Accelerated depreciation	219	23
Closing balance	4,878	(1,892)

The credits arising from accumulated income tax and social contribution losses will be offset against future taxable profit, limited to 30% thereof each year, considering the current projections of realization prepared by management.

The amounts by estimated offset period are as follows:

	June 30, 2015	**December 31, 2014**
Deferred tax assets to be recovered		
within 1 year	12,435	8,899
from 2 to 5 years	824	865
	13,259	9,764
Deferred tax liabilities to be settled		
within 1 year	503	3,778
after 5 years	7,878	7,878
	8,381	11,656

All amounts in thousands of reais unless otherwise stated

14 Investments in subsidiaries (parent company)

		June 30, 2015			
		Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Total
(a)	**Information on subsidiaries**				
	Number of quotas held	190,474,298	80,622,495	1,000,000	
	Percentage holding	99.99%	100.00%	100.00%	
	Equity (*)	207,207	102,423	14,827	324,457
	Profit for the period	723	15,130	12,743	28,596
	Unrealized profit in inventories for the current period	(4,267)			(4,267)
	Unrealized profit in inventories for the prior period	2,834			2,834
(b)	**Changes in investments**				
	At the beginning of the period	103,642	99,364	28,163	231,169
	Equity in the earnings (loss)	(710)	15,130	12,743	27,163
	Capital increase with advances for future capital increase (***)	103,410	850		104,260
	Share options granted	620	79	36	735
	Dividends received		(13,000)	(26,115)	(39,115)
	Foreign exchange variation of foreign investments	245			245
		207,207	102,423	14,827	324,457

		December 31, 2014			
		Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Total
(a)	**Information on subsidiaries**				
	Number of quotas held	87,064,319	79,772,495	1,000,000	
	Percentage holding	99.99%	100.00%	100.00%	
	Equity (*)	103,642	99,364	28,163	231,169
	Profit for the period	3,157	25,053	18,079	46,289
	Unrealized profit in inventories for the current period	(2,834)			(2,834)
	Unrealized profit in inventories merged	1,798			1,798
(b)	**Changes in investments**				
	Merger of net assets (Note 1)	101,410	76,586	25,838	203,834
	Equity in the earnings	2,121	24,661	18,031	44,813
	Acquisitions of quotas (**)		1,195	27	1,222
	Capital increase with investments		922	151	1,073
	Interest on capital		(4,000)		(4,000)
	Dividends received			(15,884)	(15,884)
	Foreign exchange variation of foreign investments	111			111
		103,642	99,364	28,163	231,169

(*) The equity of the subsidiary Ouro Fino Saúde Animal Ltda. is adjusted for the unrealized profit in inventories.

All amounts in thousands of reais unless otherwise stated

(**) Refers to the repurchase of 990,117 quotas from minority investors of the subsidiary Ouro Fino Agronegócio Ltda. and 738 quotas from the subsidiary Ouro Fino Pet Ltda., as per the Extraordinary General Meeting of stockholders held on September 25, 2014. The acquisition amount differs from the book value of the investments acquired by R$ 3,347 and R$ 21, respectively. The difference (loss) was recognized directly in the Company's equity, pursuant to item 23 of CPC 36 (R3), because it relates to a transaction with minority stockholders.

(***) On February 10, 2015, an increase in the capital of the subsidiary Ouro Fino Agronegócio Ltda. from R$ 79,772 to R$ 80,622 was approved, with advances for future capital increase made by the Company of R$ 850. On February 25, 2015, an increase in the capital of the subsidiary Ouro Fino Saúde Animal Ltda. from R$ 87,064 to R$ 190,474 was approved, with advances for future capital increase made by the Company of R$ 103,410.

Summarized financial information

Set out below is the summarized financial information for subsidiaries.

(i) Summarized balance sheet

				June 30, 2015
				Subsidiaries
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Current				
Assets	152,495	190,204	22,334	5,711
Liabilities	(94,214)	(70,400)	(7,841)	(2,742)
Current assets, net	58,281	119,804	14,493	2,969
Non-current				
Assets	258,381	23,807	592	138
Liabilities	(105,188)	(41,188)	(258)	
Non-current assets (liabilities), net	153,193	(17,381)	334	138
Equity	211,474	102,423	14,827	3,107

All amounts in thousands of reais unless otherwise stated

	December 31, 2014			
	Subsidiaries			
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Current				
Assets	186,359	221,786	35,603	5,077
Liabilities	(149,317)	(90,909)	(7,537)	(2,696)
Current assets, net	37,042	130,877	28,066	2,381
Non-current				
Assets	239,504	22,619	355	98
Liabilities	(170,070)	(54,132)	(258)	
Non-current assets (liabilities), net	69,434	(31,513)	97	98
Equity	106,476	99,364	28,163	2,479

(ii) Summarized statement of income

	Quarter ended 6/30/2015			
	Subsidiaries			
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Net sales revenue	68,593	108,408	16,056	1,837
Profit (loss) before taxation	(623)	16,112	6,823	14
Income tax and social contribution	3,474	(5,480)	(684)	(27)
Profit (loss) for the period	2,851	10,632	6,139	(13)

All amounts in thousands of reais unless otherwise stated

	Six-month period ended 6/30/2015			
				Subsidiaries
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Net sales revenue	120,870	175,649	31,751	3,391
Profit (loss) before taxation	(4,004)	22,938	14,122	485
Income tax and social contribution	4,727	(7,808)	(1,379)	(112)
Profit for the period	723	15,130	12,743	373

	Quarter ended 6/30/2014			
				Subsidiaries
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Net sales revenue	38,629	72,542	12,202	928
Profit (loss) before taxation	(2,095)	19,353	5,485	618
Income tax and social contribution	903	(6,568)	(437)	(1)
Profit (loss) for the period	(1,192)	12,785	5,048	617

	Period from 4/10/2014 to 6/30/2014			
				Subsidiaries
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Net sales revenue	38,629	72,542	12,202	928
Profit (loss) before taxation	(2,095)	19,353	5,485	618
Income tax and social contribution	903	(6,568)	(437)	(1)
Profit (loss) for the period	(1,192)	12,785	5,048	617

All amounts in thousands of reais unless otherwise stated

(iii) Statement of comprehensive income

	Quarter ended 6/30/2015	Six-month period ended 6/30/2015	Quarter ended 6/30/2014	Period from 4/10/2014 to 6/30/2014
Ouro Fino Saúde Animal Ltda. (direct subsidiary)				
Profit (loss) for the period	2,851	723	(1,192)	(1,192)
Other comprehensive income	(194)	245	(16)	(16)
Total comprehensive income (loss)	2,657	968	(1,208)	(1,208)

(iv) Summarized statement of cash flows

	Six-month period ended 6/30/2015			
	Subsidiaries			
	Direct			Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Cash flows from operating activities				
Cash provided by operating activities	3,758	10,691	21,937	627
Interest paid	(2,702)	(1,592)		
Income tax and social contribution paid		(5,727)	(1,324)	
Net cash provided by operating activities	1,056	3,372	20,613	627
Net cash used in investing activities	(19,654)	(768)	(169)	(75)
Net cash used in financing activities	(10,493)	(21,143)	(26,115)	
Increase (decrease) in cash and cash equivalents	(29,091)	(18,539)	(5,671)	552
Cash and cash equivalents at the beginning of the period	30,274	32,660	9,206	302
Exchange losses on cash and cash equivalents	(197)	(14)		
Cash and cash equivalents at the end of the period	986	14,107	3,535	854

All amounts in thousands of reais unless otherwise stated

	Period from 4/10/2014 to 6/30/2014			
	Subsidiaries			
			Direct	Indirect
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.
Cash flows from operating activities				
Cash provided by (used in) operating activities	(1,714)	(2,320)	1,130	(89)
Interest paid	(577)	(768)		
Net cash provided by operating activities	(2,291)	(3,088)	1,130	(89)
Net cash used in investing activities	(4,727)	(271)	(168)	
Net cash provided by (used in) financing activities	8,216	(3,086)		
Increase (decrease) in cash and cash equivalents	1,198	(6,445)	962	(89)
Cash and cash equivalents at the beginning of the period	3,994	9,273	768	389
Exchange losses on cash and cash equivalents	(12)	(9)		
Cash and cash equivalents at the end of the period	5,180	2,819	1,730	300

15 Intangible assets (consolidated)

	Merged balance	Additions	Provision for impairment	Write-offs	Amortization	At December 31, 2014
Trademarks and licenses purchased	716				(222)	494
Development and registration of products	37,827	10,897	(776)		(1,953)	45,995
Computer software	17,744	4,601		(37)	(2,497)	19,811
	56,287	15,498	(776)	(37)	(4,672)	66,300

	At January 1, 2015	Additions	Write-offs	Amortization	At June 30, 2015
Trademarks and licenses purchased	494			(163)	331
Development and registration of products	45,995	8,423		(1,561)	52,857
Computer software	19,811	1,306	(15)	(2,459)	18,643
	66,300	9,729	(15)	(4,183)	71,831

All amounts in thousands of reais unless otherwise stated

	At December 31, 2014			
	Cost	**Provision for impairment**	**Accumulated amortization**	**Net**
Trademarks and licenses purchased	2,198		(1,704)	494
Development and registration of products	57,656	(1,285)	(10,376)	45,995
Computer software	25,978		(6,167)	19,811
	85,832	(1,285)	(18,247)	66,300

	At June 30, 2015			
	Cost	**Provision for impairment**	**Accumulated amortization**	**Net**
Trademarks and licenses purchased	2,198		(1,867)	331
Development and registration of products	66,079	(1,285)	(11,937)	52,857
Computer software	27,269		(8,626)	18,643
	95,546	(1,285)	(22,430)	71,831

The amortization of intangible assets with product development and registration was recognized within "Cost of sales".

The development and registration of products substantially refer to expenditures for new veterinary drugs of R$ 46,923 (December 31, 2014 - R$ 39,832) and expenditures for the development of a vaccine against foot-and-mouth disease of R$ 5,934 (December 31, 2014 - R$ 6,163).

In the year ended December 31, 2014, the Group recognized an impairment loss of R$ 776.

The assumptions utilized to analyze evidence of impairment are disclosed in Note 3.1.

All amounts in thousands of reais unless otherwise stated

16 Property, plant and equipment (consolidated)

	Merged balance	Additions	Transfers	Write-offs	Depreciation	At December 31, 2014
Land	24,947					24,947
Buildings and improvements	66,696	1,591	9,260	(1,527)	(1,431)	74,589
Machinery, equipment and industrial facilities	48,462	4,690	4,835	(658)	(2,960)	54,369
Vehicles, tractors and aircraft	10,989	2,669		(7,559)	(1,037)	5,062
Furniture and fittings	2,753	851	1	(153)	(373)	3,079
IT equipment	3,549	641		(149)	(676)	3,365
Construction in progress	14,058	3,704	(14,103)	(630)		3,029
Other	2,648	125	7	(421)	(164)	2,195
	174,102	14,271		(11,097)	(6,641)	170,635

	At January 1, 2015	Additions	Transfers	Write-offs	Depreciation	At June 30, 2015
Land	24,947					24,947
Buildings and improvements	74,589				(1,097)	73,492
Machinery, equipment and industrial facilities	54,369	2,836	3,289	(3)	(2,371)	58,120
Vehicles, tractors and aircraft	5,062	1,704		(444)	(757)	5,565
Furniture and fittings	3,079	379	(169)	(8)	(283)	2,998
IT equipment	3,365	742		(9)	(518)	3,580
Construction in progress	3,029	5,219	(2,862)			5,386
Other	2,195	664	(258)	(14)	(133)	2,454
	170,635	11,544		(478)	(5,159)	176,542

	At December 31, 2014			At June 30, 2015			
	Cost	Accumulated depreciation	Net	Cost	Accumulated depreciation	Net	Annual average depreciation rates
Land	24,947		24,947	24,947		24,947	
Buildings and improvements	88,322	(13,733)	74,589	88,322	(14,830)	73,492	2.58%
Machinery, equipment and industrial facilities	81,964	(27,595)	54,369	88,086	(29,966)	58,120	6.15%
Vehicles, tractors and aircraft	14,543	(9,481)	5,062	15,803	(10,238)	5,565	21.78%
Furniture and fittings	6,245	(3,166)	3,079	6,447	(3,449)	2,998	10.25%
IT equipment	9,515	(6,150)	3,365	10,248	(6,668)	3,580	19.05%
Construction in progress	3,029		3,029	5,386		5,386	
Other	4,182	(1,987)	2,195	4,574	(2,120)	2,454	11.09%
	232,747	(62,112)	170,635	243,813	(67,271)	176,542	

The construction in progress mainly comprises the construction of the new plant of the biological products unit, amounting to R$ 3,259 (December 31, 2014 - R$ 1,799). The first phase of the work was completed in the period ended December 31, 2014, and transfers were made to "Buildings and improvements" and "Industrial facilities".

All amounts in thousands of reais unless otherwise stated

(a) Leases

Leases where the Group has substantially all the risks and rewards of ownership are classified as finance leases. Finance leases are capitalized at the inception of the lease at the lower of the fair value of the leased item and the present value of the minimum lease payments.

The net book value of leased vehicles and IT equipment totaled R$ 868 at June 30, 2015 (December 31, 2014 - R$ 584).

(b) Guarantees

Land, buildings, machinery and equipment amounting to R$ 90,149 (December 31, 2014 - R$ 89,087) are pledged as collateral for borrowings (Note 17).

17 Borrowings (consolidated)

	Financial charges	Final maturity	June 30, 2015	December 31, 2014
In foreign currency				
BNDES - FINEM	Average of foreign exchange variations of funds obtained by BNDES and weighted average rate of 2.53% p.a. (December 31, 2014 - 2.57% p.a.)	2016	568	817
Export credit note	Foreign exchange variation and weighted average rate of 4.28% p.a. (December 31, 2014 - 4.28% p.a.)	2016	5,905	10,111
Working capital	Foreign exchange variation and weighted average rate at December 31, 2014 of 1.68% p.a.	2015		53,537
In local currency				
FINEP (Technological innovation)	Weighted average rate of 4.27% p.a. (December 31, 2014 - 4.44% p.a.)	2024	148,734	122,555
BNDES - FINEM	Weighted average rate of 8.8% p.a. (December 31, 2014 - 7.89% p.a.)	2016	3,708	6,268
BNDES - FINAME	Weighted average rate of 5.14% p.a. (December 31, 2014 - 4.50% p.a.)	2022	1,158	1,276
Export credit note	Weighted average rate of 8% p.a. (December 31, 2014 - 8% p.a.)	2016	21,576	20,889
Finance lease	Weighted average of fixed interest rate of 12.08% p.a. and variable interest rate of 16.23% p.a. (December 31, 2014 - 12.32% p.a.)	2018	780	200
			182,429	215,653
Current			(64,167)	(103,093)
Non-current			118,262	112,560

BNDES - National Bank for Economic and Social Development
FINEM - Enterprise Financing Agency
FINEP - Fund for Financing of Studies and Projects
FINAME - Government Agency for Machinery and Equipment Financing

All amounts in thousands of reais unless otherwise stated

(a) Finance lease liabilities

Finance lease transactions were mainly contracted to renew the vehicle fleet.

Leases are payable as follows:

	June 30, 2015	December 31, 2014
Up to 1 year	296	200
From 1 to 3 years	484	
	780	200

(b) Guarantees for borrowings

The borrowings for research, innovation and development of products obtained from the Fund for Financing of Studies and Projects (FINEP) and which, at June 30, 2015, totaled R$ 148,734 (December 31, 2014 - R$ 122,555), are guaranteed by sureties of the related party Ouro Fino Participações e Empreendimentos S.A. and the Company, and bank guarantees of R$ 27,714. No amounts are charged for the guarantees provided.

The loan obtained from the National Bank for Economic and Social Development (BNDES), mainly for the construction of industrial facilities, purchases of Brazilian equipment and working capital, is guaranteed by the industrial plant of animal health products located in the city of Cravinhos, state of São Paulo, up to the limit of the debit balance of the borrowings, as well as the financed equipment items themselves, in addition to sureties from the controlling stockholders.

The borrowings for working capital and leases are collaterized by sureties of the parent company and/or the controlling stockholders. The borrowings from the Government Agency for Machinery and Equipment Financing (FINAME) are guaranteed through the statutory lien of the assets financed, in addition to sureties of the parent company and/or controlling stockholders.

The carrying amounts of the borrowings approximate their fair values.

The analysis of the non-current borrowings by maturity is as follows:

	June 30, 2015
from July 1, 2016 to June 30, 2017	32,361
from July 1, 2017 to June 30, 2018	35,742
from July 1, 2018 to June 30, 2019	17,706
from July 1, 2019 to June 30, 2020	7,228
from July 1, 2020 to June 30, 2021	7,048
from July 1, 2021 to June 30, 2022	7,044
from July 1, 2022 to June 30, 2023	7,031
from July 1, 2023 to June 30, 2024	4,102
	118,262

All amounts in thousands of reais unless otherwise stated

(c) Working capital borrowings in foreign currency

Swap transactions were contracted for working capital borrowings contracted in foreign currency (US$) amounting to R$ 5,905 (December 31, 2014 - R$ 63,648), to exchange the charges for those based on the CDI interest rate (Note 8).

18 Provision for contingencies (consolidated)

Certain Group companies are parties to tax, labor and civil lawsuits at various court levels. The provisions for contingencies against potentially unfavorable outcomes of litigation in progress are established and updated based on management's evaluation, as supported by legal counsel. The provisions are as follows:

	June 30, 2015	December 31, 2014
Labor	2,713	2,561
Civil, social security and tax	114	103
	2,827	2,664

In addition, certain Group companies are parties to other administrative disputes, including those related to tax assessments. No provisions were recorded to cover possible losses, based on the opinion of legal counsel. Disputes for which a favorable outcome was considered as possible totaled R$ 47,323 (December 31, 2014 - R$ 38,938), and mainly corresponded to tax (ICMS) and labor claims.

The changes in the provision for contingencies were as follows:

	June 30, 2015	December 31, 2014
Opening balance	2,664	3,135
Additions	725	750
Write-offs	(562)	(1,221)
Closing balance	2,827	2,664

19 Equity

(a) Capital

Capital was paid on April 10, 2014 in the amount of R$ 1, corresponding to 500 shares. After the merger described in Note 1, capital was represented by 188,627,485 common shares without par value, fully subscribed and paid in the amount of R$ 188,626.

At the Extraordinary General Meeting held on August 20, 2014, the stockholders approved the reverse split of all of the common shares representing the capital of the Company, in the ratio of three shares for one share of the same type, and the number of common shares totaled 62,875,828 but the ownership interest remained the same.

At the Extraordinary General Meeting held on September 25, 2014, the following resolutions were approved by the stockholders: (i) a capital increase of R$ 3,819, with the issue of 209,521 common shares. The payment was made through the contribution of the net assets representing 764,874 quotas of the subsidiary Ouro Fino Agronegócio Ltda. and 4,262 quotas of the subsidiary Ouro Fino Pet Ltda., in the amounts of R$ 3,545 and R$ 274, respectively, according to the appraisal reports issued on September 19, 2014 by a specialized company, and (ii) the reverse split of all of the common shares representing the capital of the Company, in the ratio of 1.26170698 shares for one share of the same type, and the number of common shares totaled 50,000,000 but the ownership interest remained the same.

The amount of the payment made through the contribution of assets of the subsidiaries Ouro Fino Agronegócio Ltda. and Ouro Fino Pet Ltda., which was based on the valuation carried out by a specialized company, as mentioned above, differs from the book values of the investments acquired (Note 14) by R$ 2,623 and R$ 123, respectively. The difference (loss) was recognized directly in the Company's equity, pursuant to item 23 of CPC 36 (R3), because it relates to a transaction with minority stockholders.

The Board of Directors' meeting held on October 17, 2014 approved the issue of 1,923,077 shares, which were the object of the Public Offer described in Note 1 (a), which resulted in a capital increase of R$ 51,923.

The Board of Directors' meeting held on November 18, 2014 approved the issue of 2,019,230 common shares, with a capital increase of R$ 54,520, as a result of the full exercise of the option for distribution of an additional lot of shares within the context of the Offer.

At June 30, 2015, the Company had 53,942,307 common shares.

All amounts in thousands of reais unless otherwise stated

(b) Capital reserve

The amounts considered as "Capital reserve" related to expenditures incurred for the Initial Public Offer (IPO), as shown below:

Description	Basic Operation
Capital increase	106,443
Borrowing costs	(6,392)
Direct costs(commissions)	(4,264)
Indirect costs (lawyers, auditors, consultancy and other)	(8,187)
Borrowing costs proportionate to the secondary offering	6,059
	100,051

According to Technical Pronouncement CPC 08 (R1), the indirect costs, proportionate to the secondary portion of the Offer, cannot be classified as transaction costs; accordingly, this amount was reclassified to profit or loss for the year ended December 31, 2014 because these costs are borne by the Company, as agreed between the stockholders and disclosed in the Offer process.

(c) Allocation of profit

Profit is allocated as follows, according to the bylaws:

- 5% to the legal reserve, limited to 20% of the capital;
- minimum dividend of 25% of profit adjusted according to article 202 of Law 6404; and
- the remaining balance will be distributed by the stockholders in General Meeting representing not less than two-thirds of the voting shares, in accordance with the applicable legal provisions.

At the Annual General Meeting held on April 28, 2014, the stockholders approved an additional dividend distribution of R$ 3,931 (R$ 0.07286693 per share), totaling a dividend distribution of R$ 12,889 (R$ 0.23893959 per share) of the profit for the year ended December 31, 2014.

(d) Carrying value adjustments

The carrying value adjustments in equity refer to the effect of the adoption of the deemed cost for land in subsidiaries on January 1, 2009, as well as to all exchange rate differences resulting from the translation of the balance sheet and the statement of income of the foreign subsidiaries.

(e) Stock option plan

At the Extraordinary General Meeting held on December 30, 2014, the stockholders approved a Stock Option Plan (the "Plan"), aiming at: (i) stimulating the Company's growth, success and achievement of objectives; (ii) aligning the interests of the Company's stockholders with those of the eligible individuals; (iii) enabling attracting and retaining professionals and service providers, thus stimulating the generation of value for the Company, and (iv) sharing risks and gains equally between stockholders, officers and employees.

All amounts in thousands of reais unless otherwise stated

The plan is managed by the Board of Directors and, according to its rules, the following can be eligible as beneficiaries: Officers, Employees and Service Providers of the Company or of other companies under its control. The total number of common shares for which options may be granted shall not exceed 1.5% of the total common shares of the Company's share capital. The Company's Stock Option Plan is available at the Brazilian Securities Commission (CVM).

The vesting period considers that the beneficiaries may exercise their rights in installments of 1/5 (one fifth) of the total shares granted as from the end of the first year from the date of the signature of the Adhesion Agreements, and the same number of shares annually up to the end of the fifth year, provided that the beneficiaries remain continually linked to the Company.

The exercise price will be established based on the average price of the quotations of the Company's shares on the São Paulo Stock Exchange (BM&FBOVESPA) , weighted by the trading volume, in the 60 trading sessions prior to the grant, monetarily restated by the General Market Price Index (IGP-M).

The maximum term for the exercise of the options is four years as from the end of the vesting period. Options not exercised according to the terms and conditions established will be automatically canceled, without any compensation.

(i) Options granted

At December 30, 2014, the Board of Directors approved the Plan's Regulations and Adhesion Contracts, as well as defined those elected for the first grant, totaling 809,135 stock options, distributed among 17 beneficiaries, as follows:

	End of the vesting period				
	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019
Number of options	161,827	161,827	161,827	161,827	161,827
Exercise price at launch (strike price)	28.22	28.22	28.22	28.22	28.22
Fair value of options granted	9.65	11.16	12.48	13.74	14.90
Limit date to exercise the option	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023

The fair value attributed to these options was determined based on the Black-Scholes-Merton pricing model, which takes into consideration the value of the share, the exercise price, the time to elapse up to the exercise of the option, the likelihood of the option being exercised, the historical volatility, the dividend rate and the risk-free interest rate, according to the assumptions below:

All amounts in thousands of reais unless otherwise stated

	General assumptions and information on the evaluation				
End of the vesting period	**12/31/2015**	**12/31/2016**	**12/31/2017**	**12/31/2018**	**12/31/2019**
Price of the share on the grant date	30.61	30.61	30.61	30.61	30.61
Estimated exercise price (strike price)	33.45	35.41	37.46	39.35	41.38
Estimated life time (in years)	3.0	4.0	5.0	6.0	7.0
Expected volatility	26.20%	26.20%	26.20%	26.20%	26.20%
Risk-free interest rate	12.80%	12.60%	12.40%	12.30%	12.20%

In the six-month period ended June 30, 2015, the Company and its subsidiaries recognized an expense of R$ 746 with stock options.

20 Segment information (consolidated)

The Board of Directors is the chief decision-maker and has determined the Group's operating segments according to the markets where it operates, based on strategic business decisions.

The segments are:

- Production animals - production and sale in the domestic market of veterinary drugs, vaccines and other products for production animals (cattle, pigs, poultry, sheep, horses and goats).

- Domestic animals - production and sale in the domestic market of veterinary drugs and other products for domestic animals (dogs, cats and ornamental birds).

- International operations - production and sale in the foreign market of veterinary drugs, vaccines and other products for production animals (cattle, pigs, poultry, sheep, horses and goats). Exports of these products are mainly to Latin America.

As described in Note 4.1 (b), subsidiaries have a broad customer base and, therefore, the Group does not have customers representing more than 10% of its total net revenues.

The Group has not presented assets and liabilities by business segment since they are not part of the analyses carried out by the Board of Directors when making strategic decisions.

All amounts in thousands of reais unless otherwise stated

The results by segment are as follows:

	Quarter ended 6/30/2015			
	Results by business segment			
	Production animals	**Domestic animals**	**International operations**	**Total**
Net revenue	111,898	15,216	5,582	132,696
Cost of sales	(54,375)	(3,387)	(2,078)	(59,840)
Gross profit	57,523	11,829	3,504	72,856
Selling expenses	(33,976)	(4,832)	(2,307)	(41,115)
General and administrative expenses (not segmented)				(9,424)
Other income, net (not segmented)				824
Operating profit				23,141
Finance income (not segmented)				722
Finance costs (not segmented)				(2,485)
Finance result (not segmented)				(1,763)
Profit before taxation				21,378
Income tax and social contribution				
Current (not segmented)				(9,256)
Deferred (not segmented)				6,760
Profit for the period				18,882

	Six-month period ended 6/30/2015			
	Results by business segment			
	Production animals	**Domestic animals**	**International operations**	**Total**
Net revenue	180,158	30,131	9,451	219,740
Cost of sales	(85,218)	(7,045)	(3,293)	(95,556)
Gross profit	94,940	23,086	6,158	124,184
Selling expenses	(61,226)	(9,168)	(3,838)	(74,232)
General and administrative expenses (not segmented)				(18,106)
Other income, net (not segmented)				869
Operating profit				32,715
Finance income (not segmented)				17,042
Finance costs (not segmented)				(19,536)
Finance result (not segmented)				(2,494)
Profit before taxation				30,221
Income tax and social contribution				
Current (not segmented)				(10,604)
Deferred (not segmented)				6,770
Profit for the period				26,387

All amounts in thousands of reais unless otherwise stated

	Quarter ended 6/30/2014			
	Results by business segment			
	Production animals	Domestic animals	International operations	Total
Net revenue	73,069	11,798	3,341	88,208
Cost of sales	(34,800)	(2,463)	(1,261)	(38,524)
Gross profit	38,269	9,335	2,080	49,684
Selling expenses	(21,037)	(2,797)	(562)	(24,396)
General and administrative expenses (not segmented)				(2,574)
Other income, net (not segmented)				(190)
Operating profit				22,524
Finance income (not segmented)				1,633
Finance costs (not segmented)				(3,325)
Finance result (not segmented)				(1,692)
Profit before taxation				20,832
Income tax and social contribution				
Current (not segmented)				(3,264)
Deferred (not segmented)				(2,181)
Profit for the period				15,387

	Period from 4/10/2014 to 6/30/2014			
	Results by business segment			
	Production animals	Domestic animals	International operations	Total
Net revenue	73,069	11,798	3,341	88,208
Cost of sales	(34,800)	(2,463)	(1,261)	(38,524)
Gross profit	38,269	9,335	2,080	49,684
Selling expenses	(21,037)	(2,797)	(562)	(24,396)
General and administrative expenses (not segmented)				(2,574)
Other income, net (not segmented)				(190)
Operating profit				22,524
Finance income (not segmented)				1,633
Finance costs (not segmented)				(3,325)
Finance result (not segmented)				(1,692)
Profit before taxation				20,832
Income tax and social contribution				
Current (not segmented)				(3,264)
Deferred (not segmented)				(2,181)
Profit for the period				15,387

All amounts in thousands of reais unless otherwise stated

The table below shows the analysis by country of the net revenue from international operations:

	Quarter ended June 30, 2015	Six-month period ended June 30, 2015	Quarter ended June 30, 2014	Period from 4/10/2014 to 6/30/2014
Mexico	1,837	3,391	939	939
Arab Emirates	1,199	1,728		
Panama	530	1,270	395	395
Bolivia		432		
Guatemala		61	277	277
Paraguay	45	45	529	529
Colombia			623	623
Other	1,971	2,524	578	578
	5,582	9,451	3,341	3,341

21 Revenue (consolidated)

The reconciliation between gross and net sales and service revenues is as follows:

	Quarter ended 6/30/2015	Six-month period ended 6/30/2015	Quarter ended 6/30/2014	Period from 4/10/2014 to 6/30/2014
Domestic customers				
Gross sales and services	142,446	236,394	97,121	97,121
Taxes and deductions on sales	(15,332)	(26,105)	(12,254)	(12,254)
	127,114	210,289	84,867	84,867
Foreign customers				
Gross sales	5,582	9,626	3,341	3,341
Taxes and deductions on sales		(175)		
	5,582	9,451	3,341	3,341
	132,696	219,740	88,208	88,208

All amounts in thousands of reais unless otherwise stated

22 Costs and expenses by nature

	Parent company	
	Quarter ended 6/30/2015	Six-month period ended 6/30/2015
General and administrative expenses		
Personnel	209	391
Outsourced services	87	254
Travel	2	17
Other	23	136
	321	798

	Consolidated			
	Quarter ended 6/30/2015	Six-month period ended 6/30/2015	Quarter ended 6/30/2014	Period from 4/10/2014 to 6/30/2014
Cost of sales				
Variable costs (raw and consumption materials)	39,140	61,703	24,452	24,452
Personnel	10,430	16,194	5,601	5,601
Depreciation and amortization	3,021	5,505	1,659	1,659
Outsourced services	4,339	4,778	1,887	1,887
Electricity	1,535	2,301	783	783
Other	1,375	5,075	4,142	4,142
	59,840	95,556	38,524	38,524
Selling expenses				
Personnel	15,364	30,794	9,427	9,427
Sales team	13,299	22,861	8,158	8,158
Outsourced services	4,672	7,552	1,940	1,940
Freight	4,048	6,871	2,648	2,648
Depreciation and amortization	1,084	2,149	586	586
Telecommunications and electricity	387	771	250	250
Other	2,261	3,234	1,387	1,387
	41,115	74,232	24,396	24,396
General and administrative expenses				
Personnel	6,797	13,508	4,182	4,182
Depreciation and amortization	872	1,688	583	583
Outsourced services	572	864	(3,028)	(3,028)
Travel	265	441	189	189
Telecommunications and electricity	214	424	161	161
Vehicles	34	159	136	136
Donations and sponsorships	61	124	67	67
Other	609	898	284	284
	9,424	18,106	2,574	2,574
	110,379	187,894	65,494	65,494

All amounts in thousands of reais unless otherwise stated

23 Other income (expenses), net

	Parent company	
	Quarter ended 6/30/2015	Six-month period ended 6/30/2015
Income from sales of scrap, rentals and other	25	50
Federal, state, municipal and other taxes	(3)	(11)
	22	39

	Consolidated			
	Quarter ended June 30, 2015	Six-month period ended June 30, 2015	Quarter ended June 30, 2014	Period from 4/10/2014 to 6/30/2014
Gains on disposal and write-off of PP&E	58	127	312	312
Income from sales of scrap, rentals and other	177	205		
REINTEGRA (Note 11)	874	874		
Federal, state, municipal and other taxes	(285)	(337)	(234)	(234)
Other losses			(268)	(268)
	824	869	(190)	(190)

24 Finance result

	Parent company	
	Quarter ended June 30, 2015	Six-month period ended June 30, 2015
Finance income		
Discounts obtained		2
Income from financial investments	1	1
	1	3
Finance costs		
Bank charges	(12)	(21)
Interest		(2)
Other	(1)	(11)
	(13)	(34)
Finance result	(12)	(31)

All amounts in thousands of reais unless otherwise stated

	Consolidated			
	Quarter ended June 30, 2015	Six-month period ended June 30, 2015	Quarter ended June 30, 2014	Period from 4/10/2014 to 6/30/2014
Finance income				
Gains on derivatives	(980)	9,988	333	333
Foreign exchange variations	548	3,884	1,056	1,056
Income from financial investments	918	2,680	26	26
Interest	145	284	67	67
Monetary variations	48	151		
Discounts obtained	43	55	151	151
	722	17,042	1,633	1,633
Finance costs				
Foreign exchange variations	147	(13,136)	(864)	(864)
Interest	(2,043)	(4,221)	(1,869)	(1,869)
Losses on derivatives	(180)	(1,247)	(330)	(330)
Finance charges	(365)	(655)	(136)	(136)
Bank charges	(42)	(78)	(69)	(69)
Discounts granted			(55)	(55)
Other	(2)	(199)	(2)	(2)
	(2,485)	(19,536)	(3,325)	(3,325)
Finance result	(1,763)	(2,494)	(1,692)	(1,692)

25 Income tax and social contribution expense

The income tax and social contribution expense is reconciled to the standard rates as shown below:

	Parent company			
	Quarter ended June 30, 2015	Six-month period ended June 30, 2015	Quarter ended June 30, 2014	Period from 4/10/2014 to 6/30/2014
Profit before taxation	18,882	26,373	15,058	15,058
Standard rates	34%	34%	34%	34%
	(6,420)	(8,967)	(5,120)	(5,120)
Reconciliation to the effective rate:				
Permanent differences:				
Equity in the earnings subsidiaries	6,526	9,235	5,120	5,120
Deferred taxes, not recorded	(106)	(269)		
Income tax and social contribution				

	Consolidated			
	Quarter ended June 30, 2015	**Six-month period ended June 30, 2015**	**Quarter ended June 30, 2014**	**Period from 4/10/2014 to 6/30/2014**
Profit before taxation	21,378	30,221	20,832	20,832
Standard rates	34%	34%	34%	34%
	(7,269)	(10,275)	(7,083)	(7,083)
Reconciliation to the effective rate:				
Permanent differences:				
R&D incentive	3,303	3,303		
Adjustment to the calculation of the subsidiary taxed on the deemed profit method	1,635	3,422	1,427	1,427
Adjustment to the calculation of the foreign subsidiary taxed on the rate in effect in that country	(22)	53	209	209
Deferred taxes, not recorded	(106)	(269)		
Other permanent differences	(37)	(68)	2	2
Income tax and social contribution	(2,496)	(3,834)	(5,445)	(5,445)
Reconciliation with the statement of income:				
Current	(9,256)	(10,604)	(3,264)	(3,264)
Deferred	6,760	6,770	(2,181)	(2,181)
	(2,496)	(3,834)	(5,445)	(5,445)

On May 13, 2014, Provisional Measure 627 was converted into Law 12,973, thus confirming the repeal of the Transitional Tax System (RTT) as from 2015, earlier adoption in 2014 being permitted.

The Group completed its analysis of the impacts of the provisions of this Law, both in its financial statements and in its internal control structure. Considering that the results of this analysis did not present material tax effects, the Group has decided not to elect early adoption of the rules and provisions of the new law for the year ended December 31, 2014. As from January 1, 2015 the adoption of this law became mandatory.

All amounts in thousands of reais unless otherwise stated

26 Earnings per share

(a) Basic

Basic earnings per share is calculated by dividing the profit attributable to the stockholders of the Company by the weighted average number of common shares during the period.

	Quarter ended June 30, 2015	Six-month period ended June 30, 2015	Quarter ended June 30, 2014	Period from 4/10/2014 to 6/30/2014
Profit for the period attributable to the owners of the parent company	18,882	26,373	15,058	15,058
Weighted average number of common shares in the period	53,942	53,942	49,834	49,834
Basic earnings per share	0.35004	0.48891	0.30216	0.30216

(b) Diluted

Diluted earnings per share are calculated by dividing the profit attributable to the stockholders of the Company by the weighted average number of common shares during the period, adjusted by the weighted average number of instruments with dilutive effects.

	Quarter ended June 30, 2015	Six-month period ended June 30, 2015	Quarter ended June 30, 2014	Period from 4/10/2014 to 6/30/2014
Profit for the period attributable to the owners of the parent company	18,882	26,373	15,058	15,058
Weighted average number of common shares in the period, considering instruments with dilutive effects	53,969	53,963	49,834	49,834
Diluted earnings per share	0.34987	0.48872	0.30216	0.30216

27 Employee benefits

(a) Private pension plan - defined contribution

The Group companies sponsor a defined contribution pension plan for their employees. The plan was implemented in August 2008 and is managed by Itaú Vida e Previdência S.A. The companies' contributions to the plan during the six-month period ended June 30, 2015 totaled R$ 526 (period from April 10, 2014 to June 30, 2014 - R$ 155).

(b) Profit sharing

The Group offers to their employees a variable remuneration program, calculated based on quantitative and qualitative goals established by management. During the six-month period ended June 30, 2015, the amount of the profit-sharing provision was R$ 4,132 (period from April 10, 2014 to June 30, 2014 - R$ 962).

28 Insurance cover

The Group had insurance cover for operating risks and comprehensive civil liability, with a maximum indemnity limits of R$ 295,800 at June 30, 2015. The Group's management considers these amounts to be sufficient to cover any potential liability risks and damages to the assets and loss of profits.

* * *

(A free translation of the original in Portuguese)

2Q15 and 1H15 Earnings Release

- Net revenue increased by 13.8% in 1H15 against 1H14 and reached R$ 219.7 million
- Profit increased by 20.5% and totaled R$ 26.4 million in 1H15
- Four new products were launched in 1H15

Conference Call

In Portuguese with simultaneous translation into English
August 12, 2015
3:00 P.M. (BRT) / 2:00 P.M. (US EST)
Phone:
Brazil: +55 11 2188 0155
Other countries: +1 646 843 6054
Password: Ourofino

Investor Relations

Fábio Lopes Júnior
Bruno Menegazzo
Isabel Leandro

Phone:
(16) 3518-2000
E-mail:
ri@ourofino.com
Website:
ri.ourofino.com

2Q15 and 1H15 Earnings Release

(A free translation of the original in Portuguese)

CONTENTS

Cravinhos, August 11, 2015 – Ouro Fino Saúde Animal Participações S.A. ("Company" or "Ouro Fino") (BM&FBovespa: OFSA3), which is mainly engaged in the research, development, production and sale of veterinary drugs, vaccines and other products for production and companion animals, announces its financial results for the period ended June 30, 2015 (2Q15 and 1H15).

MESSAGE FROM MANAGEMENT

During the first half of 2015, the Company's performance was consistent with its strategy of profitable growth and value creation for its stockholders. Despite the unfavorable macroeconomic environment, in 1H15 the Company had accumulated net revenue of R$ 219.7 million, an increase of 13.8% as compared to 1H14, and profit of R$ 26.4 million, an increase of 20.5% as compared to 1H14.

In the first half of the year we launched four new products, showing our commitment to innovation and continued investments in research and development to expand our portfolio. In addition, we would point out the successful return to our product portfolio of Master, a product designed to kill internal and external parasites in cattle.

We also continued to implement the Company's restructuring plan in the international operations segment. We believe that better results can be achieved through this initiative.

We remain optimistic about the opportunities in the market in which we operate and are confident in the success of our planning for growth, by preparing for the new cycle based on the expansion of our product portfolio and continuity of the process for structuring our Biological Product area. We thank you for trusting our team!

Dolivar Coraucci Neto
CEO

Fábio Lopes Júnior
CFO and Investor Relations Officer

Information on the financial statements

Considering that the Company was established on April 10, 2014, its parent company and consolidated financial statements ("consolidated") for the quarter ended June 30, 2015 do not include information on results for comparison purposes. In this context, management decided to disclose in this Earnings Release, where applicable, information derived from the pro forma combined consolidated financial statements ("pro forma combined") of the Company's subsidiaries for the mentioned quarter.

The financial information for 2Q14 and 1H14 presented in this Earnings Release was adjusted to better reflect profit and EBITDA from continuing operations in the mentioned periods.

HIGHLIGHTS

- Net sales revenue increased by 13.8% in 1H15 to R$ 219.7 million against R$ 193.1 million in 1H14;
- Profit increased by 20.5% in 1H15 to R$ 26.4 million against R$ 22.0 million in 1H14;
- Four new products were launched in 1H15.

FINANCIAL PERFORMANCE

R$ million	**2Q14**	**2Q15**	**Variation %**	**1H14**	**1H15**	**Variation %**
Net revenue	118.1	132.7	12.4%	193.1	219.7	13.8%
Cost of sales	(48.8)	(59.9)	22.7%	(77.0)	(95.6)	24.2%
Gross profit	**69.3**	**72.8**	**5.1%**	**116.1**	**124.1**	**6.9%**
(gross margin)	*58.7%*	*54.9%*	*-3.8 p.p.*	*60.1%*	*56.5%*	*-3.6 p.p.*
Selling, general and administrative expenses	(45.6)	(49.7)	9.0%	(83.8)	(91.4)	9.1%
Operating profit	**23.7**	**23.1**	**-2.5%**	**32.3**	**32.7**	**1.2%**
(operating margin)	*20.1%*	*17.4%*	*-2.7 p.p.*	*16.7%*	*14.9%*	*-1.8 p.p.*
Finance result	(2.3)	(1.8)	-21.7%	(5.1)	(2.5)	-51.0%
Income tax and social contribution	(5.1)	(2.4)	-52.9%	(5.3)	(3.8)	-28.3%
Profit from continuing operations (2Q14 – *pro forma*)	**16.3**	**18.9**	**16.0%**	**21.9**	**26.4**	**20.5%**
profit margin from continuing operations (2Q14 –pro forma)	*13.8%*	*14.2%*	*0.4 p.p.*	*11.3%*	*12.0%*	*0.7 p.p.*
EBITDA (2Q14 and 1H14 - adjusted)	**28.9**	**28.0**	**-3.1%**	**41.2**	**42.0**	**1.9%**
EBITDA margin (2Q14 and 1H14 - adjusted)	*24.5%*	*21.1%*	*-3.4 p.p.*	*21.3%*	*19.1%*	*-2.2 p.p.*

Net revenue

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Net sales revenue	**118.1**	**132.7**	**12.4%**	**193.1**	**219.7**	**13.8%**
Production animals	96.5	112.0	16.1%	154.8	180.2	16.4%
Companion animals	16.1	15.2	-5.6%	27.9	30.1	7.9%
International operations	5.5	5.5	0.0%	10.4	9.4	-9.6%

The Company presented net revenue of R$ 219.7 million in 1H15, which represented an increase of 13.8% as compared to 1H14. In 2Q15, net revenue increased by 12.4% and reached R$ 132.7 million.

Net Revenue - Evolution
(R$ million)





- The **Production Animals** segment had net revenue of R$ 180.2 million in 1H15, an increase of 16.4% as compared to 1H14. In 2Q15, revenues reached R$ 112.0 million, an increase of 16.1% as compared to 2Q14.

  A highlight in 1H15 as compared to 1H14 was the increase in the sales of products designed to control internal and external parasites in cattle, the growth of sales in poultry and swine lines and the additional revenue from the sale of new products.

- The **Companion Animals** segment had net revenue of R$ 30.1 million in 1H15, an increase of 7.9% as compared to 1H14. In 2Q15, net revenue totaled R$ 15.2 million, a decrease of 5.6% as compared to 2Q14, which recorded an unusually higher volume of sales.

- The **International Operations** segment had net revenue of R$ 9.4 million in 1H15, a decrease of 9.6% as compared to 1H14, mainly as a result of the limitation on sales to Venezuela. In 2Q15, revenues totaled R$ 5.5 million, remaining flat as compared to 2Q14.

Cost of sales

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Cost of sales	(48.8)	(59.9)	22.7%	(77.0)	(95.6)	24.2%

The increase of 3.6 p.p. in net sales revenue in 1H15 and 3.8 p.p. in 2Q15, as compared to the same periods in 2014, reflect a mix of less favorable products with lower percentage in the international operations and the companion animals segments, a higher increase in the poultry and swine lines and lower prices of vaccines against foot-and-mouth disease.

Gross profit and gross margin

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Gross profit	**69.3**	**72.8**	**5.1%**	**116.1**	**124.1**	**6.9%**
(gross margin)	58.7%	54.9%	*-3.8 p.p.*	60.1%	56.5%	*-3.6 p.p.*

Gross profit reached R$ 124.1 million in 1H15, with a gross margin of 56.5% and a decrease of 3.6 p.p. as compared to the margin presented in 1H14. In 2Q15, it reached R$ 72.8 million, with a gross margin of 54.9% and a decrease of 3.8 p.p. as compared to 2Q14. This reduction in margin reflects the mix of less favorable products, as explained above.



Selling, general and administrative expenses

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Selling, general and administrative expenses	**(45.6)**	**(49.7)**	**9.0%**	**(83.8)**	**(91.4)**	**9.1%**
Percentage on net revenue	*38.6%*	*37.5%*	*-1.1 p.p.*	*43.4%*	*41.6%*	*-1.8 p.p.*

In 1H15, selling, general and administrative expenses totaled R$ 91.4 million, representing a dilution of 1.8 p.p. on net revenue. In 2Q15, these expenses totaled R$ 49.7 million, a dilution of 1.1 p.p.

EBITDA and EBITDA Margin

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Profit from continuing operations (2Q14 – *pro forma*)	**16.3**	**18.9**	**16.0%**	**21.9**	**26.4**	**20.5%**
(-) Discontinued operations				(0.5)		-100.0%
(-) Pro forma adjustments (apportionment of corporate services)	1.4		-100.0%			
Combined profit	**17.7**	**18.9**	**6.8%**	**21.4**	**26.4**	**23.4%**
(+) Finance result, net	2.3	1.8	-21.7%	5.1	2.5	-51.0%
(+) Income tax and social contribution	5.8	2.4	-58.6%	5.3	3.8	-28.3%
(+) Depreciation and amortization	4.4	4.9	11.4%	8.1	9.3	14.8%
EBITDA	**30.2**	**28.0**	**-7.3%**	**39.9**	**42.0**	**5.3%**
(+) Discontinued operations				0.5		-100.0%
(+) Pro forma adjustments (apportionment of corporate services) before income tax and social contribution	(2.1)		-100.0%			
(+) Other	0.8		-100.0%	0.8		-100.0%
EBITDA (2Q14 and 1H14 - adjusted)	**28.9**	**28.0**	**-3.1%**	**41.2**	**42.0**	**1.9%**
Net sales revenue	118.1	132.7	12.4%	193.1	219.7	13.8%
EBITDA margin	***25.6%***	***21.1%***	***-4.5 p.p.***	***20.7%***	***19.1%***	***-1.6 p.p.***
EBITDA margin (2Q14 and 1H14 - adjusted)	***24.5%***	***21.1%***	***-3.4 p.p.***	***21.3%***	***19.1%***	***-2.2 p.p.***

In 1H15, EBITDA was R$ 42.0 million, with an increase of 1.9% as compared to the adjusted EBITDA for 1H14. The EBITDA margin on net revenue decreased by 2.2 p.p. as compared to the same period in 2014, and was affected by the reduction in the gross margin for the period, but partially offset against the dilution of selling, general and administrative expenses. The same happened to EBITDA in 2Q15, which totaled R$ 28.0 million, a reduction of 3.1% as compared to 2Q14, and an EBITDA margin lower by 3.4 p.p. as compared to 2Q14. In 2Q15, the same effect of the reduction in the gross margin with partial offset against the dilution of selling, general and administrative expenses is noted.

EBITDA (2Q14 and 1H14 - adjusted)



Finance result

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Finance result	**(2.3)**	**(1.8)**	**-21.7%**	**(5.1)**	**(2.5)**	**-51.0%**

Finance result increased by 51.0% in 1H15 and decreased by 21.7% in 2Q15, substantially by the decrease in the net bank debt, due to the capitalization resulting from the IPO.

Income tax and social contribution

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Income tax and social contribution	**5.1**	**2.4**	**-52.9%**	**5.3**	**3.8**	**-28.3%**
Percentage on profit before income tax and social contribution	*23.8%*	*11.3%*	*-12.5 p.p.*	*19.5%*	*12.6%*	*-6.9 p.p.*

The reduction in income tax and social contribution in 2Q15 and 1H15 substantially reflects the use of more tax legislation (*Lei do Bem*) benefits (Investments in R&D).

Profit

R$ million	2Q14	2Q15	Variation %	1H14	1H15	Variation %
Profit from continuing operations (2Q14 and 1H14 - adjusted)	**16.3**	**18.9**	**16.0%**	**21.9**	**26.4**	**20.5%**
profit margin (2Q14 and 1H14 - adjusted)	*13.8%*	*14.2%*	*0.4 p.p.*	*11.3%*	*12.0%*	*0.7 p.p.*

In 1H15, profit from continuing operations reached R$ 26.4 million, an increase of 20.5% as compared to 1H14. In 2Q15, it totaled R$ 18.9 million, an increase of 16% as compared to 2Q14. The growth observed resulted from the dilution of SG&A expenses, improvement in finance result, and the lower income tax and social contribution rates applied.



Indebtedness

In R$ million	June 30, 2015	June 30, 2014
Current	64.2	66.5
Non-current	118.3	150.2
Gross debt	**182.5**	**216.7**
(-) Derivative financial instruments, net	1.5	2.6
Derivatives net debt	**181.0**	**214.1**
(-) Cash and cash equivalents	19.5	10.0
Net debt	**161.5**	**204.1**
Average cost of debt (year)[1]	**5.75%**	**6.27%**
Net debt/Adjusted annual EBITDA	**1.63**	**2.20**

Note[1]: Average cost calculated on the net debt considering corresponding derivatives.



Debt aging considers the full year between 1st of July and 30th of June the following year.

Launch of Products

Of the 121 veterinary products Ourofino owns, four were launched in 1H15. For the next years, 38 products, which are already in our pipeline, are expected to be launched.

Launches in the 1st quarter

	NAME	Indication	Category	Line
	**Lactofur**	For the treatment of severe infections in dairy and beef cattle and swine.	Antimicrobial	Production Animals
	**Ciprolac** *Dry Cow*	For the prevention and healing of mastitis (mammary gland infection) in the dry period, for the cows to produce more milk of a better quality.	Antimicrobial	Production Animals

Launches in the 2nd quarter

	NAME	Indication	Category	Line
	**Isocox**	For treatment of a disease called black diarrhea, the symptoms of which include blood in the feces of the cattle.	Other	Production Animals
	**Trissulfin SID**	For the treatment of infections in intestinal, urinary and respiratory tracts, skin and ear infections and also for the treatment of *isospora canis*, caused by agents that are sensitive to its spectrum of action.	Antibiotic & Therapeutic	Companion Animals

Investments in Research and Development

In 1H15, approximately 7.5% of net revenue was invested in R&D, totaling about R$16.5 million. The chart below shows the Company's investments in R&D in the period from January 1, 2013 to June 30, 2015.



Seasonality

An important factor for the seasonality of sales are the foot-and-mouth disease vaccination campaigns. To increase control by the government in this regard, the Ministry of Agriculture, Cattle Breeding and Supply (MAPA) establishes specific dates during the year for vaccination. With respect to foot-and-mouth disease, vaccination is scheduled mostly in two periods: the first half of the year (April and May) and the second half of the year (October and November). This fact has a direct effect on the sales of vaccines, considering that vaccination programs are mandatory for producers, under penalty of having the sales of their production interrupted in the event of non-compliance.

Together with the campaigns, management of cattle for vaccination significantly influences the use of veterinary products. We live in a large country where the extensive production system prevails. As a result, producers, in general, choose specific periods of the year, such as those on which the vaccination campaigns against foot-and-mouth disease are conducted to also make use of other products that are normally used in animals (non-mandatory vaccines, internal and external parasiticides, vermifuge, etc.). Therefore, higher sales of these other products also take place during these periods.

We also have in our portfolio some products that are not subject to the impact of the factors mentioned above, but have their seasonality related to other health programs adopted by producers in some areas, and this is more common in animals subject to more intensive systems, such as poultry, swine and dairy cattle.

For illustrative purposes only, in the fiscal years ended December 31, 2013 and 2014 the Company's revenue was distributed as follows among the quarters:

Net revenue - Fiscal Year	**1st Quarter**	**2nd Quarter**	**3rd Quarter**	**4th Quarter**
Ended December 31, ***2013***	14.4%	25.4%	24.6%	35.6%
Ended December 31, ***2014***	17.4%	27.3%	24.0%	31.3%



PERFORMANCE OF THE SHARES

Ourofino shares started to be traded on the São Paulo Stock Exchange (BM&F Bovespa) on October 21, 2014 under the ticker OFSA3, with an initial quotation of R$27.00. The chart below presents the behavior of the share price between the first trading day (10/21/2014) and the last day of 2Q15 (6/30/2015).

OFSA3 closed the day on 6/30/2015 quoted at R$32.00[1], with a variation of 19.54% since the start of the trading. In the same period, Ibovespa presented a depreciation of 3.25%. The average daily trading volume since the IPO date was R$ 1.4 million.



Statement of income (R$ thousands)	2Q15[1]	2Q14[2]	1H15[1]	1H14[2]
Discontinued operations				
Revenue	132,696	118,128	219,740	193,088
Cost of sales	(59,840)	(48,795)	(95,556)	(76,977)
Gross profit	**72,856**	**69,333**	**124,184**	**116,111**
Selling expenses	(41,115)	(37,746)	(74,232)	(67,562)
General and administrative expenses	(9,424)	(7,705)	(18,106)	(15,976)
Other income, net	824	(151)	869	(250)
Operating profit	**23,141**	**23,731**	**32,715**	**32,323**
Finance income	722	4,140	17,042	9,072
Finance costs	(2,485)	(6,394)	(19,536)	(14,133)
Finance result	(1,763)	(2,254)	(2,494)	(5,061)
Profit before income tax and social contribution	**21,378**	**21,477**	**30,221**	**27,262**
Income tax and social contribution - Current	(9,256)	(2,676)	(10,604)	(3,853)
Income tax and social contribution - Deferred	6,760	(2,451)	6,770	(1,458)
Earnings for the period from continuing operations	**18,882**	**16,350**	**26,387**	**21,951**
Discontinued operations				
Loss for the year from discontinued operations	-	(105)		(580)
Profit for the period	**18,882**	**16,245**	**26,387**	**21,371**

[1] Consolidated statement of income

[2] Combined consolidated statement of income

Statement of cash flows (R$ thousands)	1H15[1]	1H14[2]
Cash flows from operating activities		
Profit before income tax and social contribution, including discontinued operations	**30,221**	**26,682**
Adjustments for:		
Provision for impairment of trade receivables	(394)	170
Provision for inventory losses and write-offs	138	(750)
Provision for losses on advances		242
Depreciation and amortization	9,342	8,154
Provision for impairment of intangible assets		766
Gains on disposal of property, plant and equipment	(127)	(425)
Interest and monetary and exchange variations, net	14,000	5,684
Unrealized derivative financial instruments	(8,741)	951
Provision for (reversal of) contingencies	163	(128)
Share options granted	746	
Other losses		
Changes in working capital		
Trade receivables	2,777	7,053
Inventories	(32,097)	(32,070)
Taxes recoverable	(3,295)	(1,201)
Other assets	(1,342)	5,418
Trade payables	10,466	(5,414)
Taxes and charges payable	(1,176)	(3,600)
Other liabilities	(1,709)	2,526
Cash from operations	**18,972**	**14,058**
Interest paid	(4,294)	(4,513)
Income tax and social contribution paid	(7,050)	(1,001)
Net cash provided by operating activities	**7,628**	**8,544**
Cash flows from investing activities		
Borrowings received - related parties		
Investments in intangible assets	(9,729)	(8,155)
Purchase of property, plant and equipment	(11,544)	(11,423)
Proceeds from sale of property, plant and equipment	606	1,136
Net cash used in investing activities	**(20,667)**	**(18,442)**
Cash flows from financing activities		
Proceeds from borrowings	43,500	17,620
Repayment of borrowings	(86,769)	(26,519)
Realized derivative financial instruments	16,463	
Borrowings received - related parties		13,600
Borrowings repaid - related parties		(13,780)
Advances for future capital increase		
Dividends and interest on capital paid	(12,889)	(9,107)
Net cash provided by financing activities	**(39,695)**	**(18,186)**
Increase in cash and cash equivalents, net	**(52,734)**	**(28,084)**
Cash and cash equivalents at the beginning of the year	**72,453**	**38,423**
Foreign exchange gains (losses) on cash and cash equivalents	**(211)**	**(310)**
Cash and cash equivalents at the end of the year	**19,508**	**10,029**

[1] Consolidated statement of cash flows

[2] Combined consolidated statement of cash flows

Balance Sheet (R$ thousands)	6/30/2015[1]	12/31/2014[1]
Assets		
Current assets	**333,101**	**365,616**
Cash and cash equivalents	19,508	72,453
Trade receivables	175,354	178,111
Derivative financial instruments	2,785	10,376
Inventories	119,369	86,848
Taxes recoverable	6,107	6,905
Income tax and social contribution recoverable	1,297	2,486
Related parties	1,403	998
Other assets	7,278	7,439
Non-current assets	**281,691**	**261,645**
Long-term receivables	**33,318**	**24,710**
Taxes recoverable	26,989	22,529
Deferred income tax and social contribution	4,878	1,920
Other assets	1,451	261
Permanent assets	**248,373**	**236,935**
Intangible assets	71,831	66,300
Property, plant and equipment	176,542	170,635
Total assets	**614,792**	**627,261**
Liabilities and equity		
Current liabilities	**140,207**	**176,904**
Trade payables	33,918	22,390
Derivative financial instruments	1,307	12
Borrowings	64,167	103,093
Salaries and social charges	22,772	24,912
Taxes payable	4,022	5,638
Income tax and social contribution payable	3,363	763
Dividends and interest on capital		8,959
Related parties	284	
Commissions on sales	5,533	5,669
Other liabilities	4,841	5,468
Liabilities related to non-current assets held for sale		
Non-current liabilities	**121,089**	**120,200**
Derivative financial instruments		1,164
Borrowings	118,262	112,560
Provision for contingencies	2,827	2,664
Deferred income tax and social contribution		3,812
Total liabilities	**261,296**	**297,104**
Total equity	**353,385**	**330,069**
Non-controlling interests	111	88
Total liabilities and equity	**614,792**	**627,261**

[1] Consolidated balance sheet